Details of the Drug

General Information of Drug (ID: DMCMBHA)

• Drug Name: Erlotinib
• Synonyms: Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-Quinazolinamine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline; 4-[(3-ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline

Indication

Disease Entry	ICD 11	Status	REF
Adrenal gland neoplasm	N.A.	Approved	[1]
Adult hepatocellular carcinoma	N.A.	Approved	[1]
Brain cancer	2A00	Approved	[1]
Esophageal disorder	N.A.	Approved	[1]
Lung cancer	2C25.0	Approved	[1]
Non-small-cell lung cancer	2C25.Y	Approved	[2]
Pancreatic adenocarcinoma	N.A.	Approved	[1]
Psoriasis	EA90	Approved	[1]
Salivary gland squamous cell carcinoma	N.A.	Approved	[1]
Pancreatic cancer	2C10	Phase 3	[2]
Colon cancer	2B90.Z	Phase 2	[2]
Ependymoma	2A00.0Y	Investigative	[1]
Neoplastic meningitis	N.A.	Investigative	[1]
Neuroblastoma	2D11.2	Investigative	[1]

• Therapeutic Class: Anticancer Agents
• Affected Organisms: Humans and other mammals
• ATC Code:
  L01EB02: Erlotinib
  L01EB: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
  L01E: PROTEIN KINASE INHIBITORS
  L01: ANTINEOPLASTIC AGENTS
  L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 1:
  Molecular Weight (mw); 393.4
  Logarithm of the Partition Coefficient (xlogp); 3.3
  Rotatable Bond Count (rotbonds); 11
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 7
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
  Bioavailability: 59% of drug becomes completely available to its intended biological destination(s) [4]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 1.69 mL/min/kg [5]
  Elimination: 0.3% of drug is excreted from urine in the unchanged form [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 36.2 hours [5]
  Metabolism: The drug is metabolized via the liver []
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 5.446 micromolar/kg/day [6]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.07% [5]
  Vd: The volume of distribution (Vd) of drug is 232 L []
  Water Solubility: The ability of drug to dissolve in water is measured as 0.4 mg/mL [3]
• Chemical Identifiers:
  Formula: C22H23N3O4
  IUPAC Name: N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
  Canonical SMILES: COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC
  InChI: InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)
  InChIKey: AAKJLRGGTJKAMG-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 176870
  ChEBI ID: CHEBI:114785
  CAS Number: 183321-74-6
  UNII: J4T82NDH7E
  DrugBank ID: DB00530
  TTD ID: D07POC
  VARIDT ID: DR00558
  INTEDE ID: DR0603
  ACDINA ID: D00239
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Epidermal growth factor receptor (EGFR)	TTGKNB4	EGFR_HUMAN	Inhibitor	[7]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[8]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[9]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[10]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[11]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[11]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[11]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Epidermal growth factor receptor (EGFR)	OTAPLO1S	EGFR_HUMAN	Drug Response	[12]

Molecular Expression Atlas of This Drug

• The Studied Disease: Adrenal gland neoplasm

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Epidermal growth factor receptor (EGFR)	DTT	EGFR	2.09E-05	0.4	190.08
Epidermal growth factor receptor (EGFR)	DTT	EGFR	6.32E-04	0.39	1.69
P-glycoprotein 1 (ABCB1)	DTP	P-GP	3.21E-01	-1.31E-01	-9.67E-02
Breast cancer resistance protein (ABCG2)	DTP	BCRP	9.24E-02	-8.49E-01	-5.22E-01
Cytochrome P450 1A2 (CYP1A2)	DME	CYP1A2	6.80E-01	-3.78E-02	-2.75E+00
Cytochrome P450 1A2 (CYP1A2)	DME	CYP1A2	6.78E-06	-1.01E+00	-3.20E+00
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	7.76E-01	-2.05E-01	-5.72E+00
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	9.78E-01	-1.22E-03	-4.10E-03
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	5.73E-01	-1.42E-01	-5.35E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	2.09E-09	-9.49E-01	-8.32E+00
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	5.50E-01	-9.32E-02	-1.01E+00
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	2.15E-08	-6.60E-01	-3.96E+00

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 45 Cell Line(s) in Bone Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
RPMI-3460/CS1	GDSC2	3.1979	5.5801	0.1794	1.3459
EW-24	GDSC1; GDSC2	-0.1789	5.1739	-2.1356	22.9141
CADO-ES1	GDSC2	1.2533	7.837	-2.2098	18.6207
CHSA8926	GDSC2	1.6559	4.309	-0.1448	5.5476
EW-7	GDSC2	1.7294	5.5604	-0.7045	8.8101
ES6	GDSC1; GDSC2	1.9078	11.4855	-3.5068	22.5326
NOS-1 [Human HNSCC]	GDSC1; GDSC2	1.9516	11.8974	-3.6774	23.0608
EW-1	GDSC1; GDSC2	2.2664	4.8264	0.0109	3.397
ES8	GDSC1; GDSC2	2.3176	5.203	-0.1313	4.1138
EW-22	GDSC2	2.3287	5.0694	-0.0629	3.7051
SK-PN-DW	GDSC1; GDSC2	2.4436	5.3411	-0.1181	3.8175
NY	GDSC2	2.6359	5.3407	-0.0063	2.9007
EW-13	GDSC1; GDSC2	2.8895	4.8297	0.3374	0.9859
EW-11	GDSC1; GDSC2	3.0268	8.2381	-1.1015	8.2865
EW-16	GDSC1; GDSC2	3.086	10.9442	-2.3592	14.7013
EW-18	GDSC1; GDSC2	3.0968	5.6118	0.1184	1.7058
CAL-72	GDSC2	3.1838	5.0655	0.3736	0.6462
ES1	GDSC1; GDSC2	3.1927	11.6449	-2.6243	15.6995
Hs 888.T	CTRP2	3.2172	9.2347	1.7441	24.1821
ES7	GDSC1; GDSC2	3.2958	5.8248	0.1264	1.4733
HuO9	GDSC2	3.4561	6.1408	0.0739	1.541
EW-12	GDSC1; GDSC2	3.4834	5.974	2.1279	6.8565
SK-ES-1	GDSC1; GDSC2; CTRP2; CCLE	3.5515	7.1411	2.9617	18.7441
HuO-3N1	GDSC2	3.6293	5.9187	0.2368	0.8064
ES5	GDSC1; GDSC2	3.8108	6.055	2.3383	4.7708
H-EMC-SS	GDSC1; GDSC2	4.2529	6.3878	0.3096	0.337
CHSA0108	GDSC2	4.5303	13.162	-0.6309	19.4974
U-CH2	GDSC2	4.6675	9.3728	1.3312	9.0788
EW-3	GDSC1; GDSC2	4.7824	6.6923	0.3919	0.1117
CHSA0011	GDSC2	5.0827	8.113	2.1859	3.4022
TC-71	GDSC1; GDSC2; CCLE	5.1421	6.9599	2.396	0.5007
MHH-ES-1	GDSC2; CTRP2; CCLE	5.1638	8.8248	3.866	11.0086
ES4	GDSC1; GDSC2	5.1796	14.8526	-2.8302	12.7091
SaOS-2	GDSC2; CTRP2; CCLE	5.2976	8.0198	4.3816	8.578
SK-N-MC	CTRP2	5.6815	8.9861	4.2611	8.2264
U2OS	GDSC2; CTRP2; CCLE	5.6856	9.6338	3.9426	9.549
CAL-78	GDSC2; CTRP2; CCLE	5.8226	10.1858	3.7861	9.9218
A-673	GDSC2; CTRP2; CCLE	6.3869	10.2192	4.2351	6.9677
TC71	CTRP2	6.4608	9.9403	4.4317	6.0159
Hs 822.T	CTRP2	6.6526	10.4563	4.3225	6.1439
SJSA-1	GDSC1; GDSC2; CTRP2; CCLE	6.7897	10.4731	4.4163	5.5312
MG-63	GDSC2; CTRP2; CCLE	7.395	11.5201	4.3339	4.9606
SW1353	CTRP2; CCLE	7.4651	11.1002	4.5797	3.8931
G-292 clone A141B1	GDSC2; CTRP2	7.7103	13.4191	3.6361	7.2953
HOS	GDSC2; CTRP2; CCLE	7.8626	13.5308	3.6866	6.8769

Cancer Drug Sensitivity Data Curated from 223 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
JK1	CTRP2	1.1957	4.6389	1.0598	32.7494
MEC1	CTRP2	4.5295	7.3767	3.9034	12.4274
JM1	GDSC1; GDSC2; CTRP2	5.9077	9.0401	4.4311	7.0493
GA-10	GDSC1; GDSC2	0.1783	4.1246	-1.2907	16.9728
MOLM-16	GDSC2; CTRP2	1.004	4.0045	0.9376	33.7976
P30/OHK	GDSC1; GDSC2	1.3964	3.5666	0.0302	5.0795
Sc-1	GDSC1	1.4338	3.4931	0.0939	5.7191
Karpas-231	GDSC1; GDSC2	1.4753	3.535	0.1035	4.4348
SUP-B8	GDSC2	1.4758	4.6506	0.8357	22.0384
Jiyoye	GDSC1; GDSC2	1.5116	4.0159	-0.1057	5.6451
MHH-CALL-2	GDSC2	1.5615	4.3504	-0.2334	6.3172
EoL-1	GDSC1; GDSC2; CTRP2	1.6361	2.5282	1.6361	29.3689
Hs 445	GDSC1; GDSC2	1.6727	4.7007	-0.324	6.6119
SCC-3	GDSC1; GDSC2	1.6751	3.1969	0.4002	2.2248
MV4-11	GDSC1; GDSC2; CTRP2	1.6901	4.1697	1.6434	29.1653
JVM-2	GDSC1; GDSC2	1.7267	3.4788	0.3012	2.7039
JSC-1	GDSC1; GDSC2	1.8176	4.1061	0.064	3.9276
H9	GDSC1; GDSC2	1.8259	4.1484	0.0495	3.9977
BE-13	GDSC1; GDSC2	1.8345	3.9158	0.1651	3.2955
CTB-1	GDSC1; GDSC2	1.8461	5.693	0.7587	20.2622
KMS-26	CTRP2; CCLE	1.8543	2.959	1.854	27.916
KOPN-8	GDSC1; GDSC2	1.8552	4.5644	-0.1297	5.0133
SU-DHL-5	GDSC2	1.864	7.3517	-1.4877	13.0843
TK [Human B-cell lymphoma]	GDSC1; GDSC2	1.9087	3.6896	0.3159	2.2943
697	GDSC1; GDSC2; CTRP2; CCLE	1.9543	3.62	1.9474	27.2719
Karpas-1106P	GDSC2	1.9685	3.7032	0.3447	2.0375
P32/ISH	GDSC1; GDSC2	2.0396	4.4003	0.0683	3.4725
MOLM-13	GDSC1; GDSC2; CTRP2	2.0693	4.5551	2.0038	26.7037
Pfeiffer	CTRP2; CCLE	2.1084	3.5643	2.1049	26.2336
ME1	GDSC1; GDSC2	2.1691	3.6162	0.4899	1.0345
MOLT-4	GDSC1; GDSC2	2.183	4.4503	0.1326	2.8574
NOMO-1	GDSC1; GDSC2	2.2004	3.7023	0.4696	1.0927
CCRF-CEM	GDSC1; GDSC2	2.244	4.2733	0.2469	2.1424
VAL	GDSC1; GDSC2	2.2755	4.3372	0.2362	2.1527
CESS	GDSC1; GDSC2	2.2972	4.0202	0.3848	1.377
JURL-MK1	GDSC1; CTRP2	2.3194	4.2704	2.293	24.9049
HC-1	GDSC1; GDSC2	2.3485	7.1753	-1.0489	9.4094
SEM	CTRP2	2.3919	4.4281	2.3566	24.4523
HAL-01	GDSC1; GDSC2	2.4358	4.302	0.3364	1.4426
ALL-PO	GDSC1; GDSC2	2.4506	7.1524	-0.9673	8.7133
BALL-1	GDSC1; GDSC2	2.4944	4.3398	0.3498	1.3145
NCO2	CTRP2; CCLE	2.5051	4.2612	2.4862	23.6425
CTV-1	GDSC1; GDSC2	2.5669	4.3343	0.3871	1.0759
IM-9	GDSC1; GDSC2	2.5799	3.9537	0.5421	0.4823
BV-173	GDSC1; GDSC2; CTRP2	2.5841	4.6702	2.5357	23.2162
Karpas-45	GDSC1; GDSC2	2.5938	5.394	-0.0539	3.2189
Ku812	GDSC1; GDSC2; CTRP2; CCLE	2.5972	4.0195	2.5909	22.9869
Mono-Mac-1	CTRP2; CCLE	2.6074	5.665	2.3899	23.6482
Ramos.2G6.4C10	GDSC1; GDSC2	2.6499	4.2925	0.4418	0.7831
KYO-1	CTRP2	2.6816	4.704	2.6351	22.56
Peer	CTRP2	2.7186	3.756	2.7178	22.1597
MLMA	GDSC1; GDSC2	2.7387	4.6999	0.3199	1.1936
NU-DUL-1	GDSC1; GDSC2; CTRP2	2.7404	4.1449	2.7332	22.0359
KMOE-2	GDSC1; GDSC2	2.7522	5.2476	0.0975	2.2076
JVM-3	GDSC1; GDSC2; CTRP2; CCLE	2.8007	5.4168	2.6539	22.1138
LAMA-84	GDSC1; GDSC2; CTRP2	2.8113	4.4903	2.7894	21.6129
Loucy	GDSC1; GDSC2	2.861	9.0579	-1.6033	11.3689
ATN-1	GDSC1; GDSC2	2.8698	5.2684	0.1491	1.8162
L-1236	GDSC1; GDSC2	2.87	4.909	0.2969	1.1654
CMK-86	CCLE	2.875	5.583	1.6029	7.8862
MOLT-16	GDSC1; GDSC2; CTRP2; CCLE	2.9221	4.9909	2.8561	21.0248
YT	GDSC1; GDSC2	2.9492	4.422	0.5173	0.3575
MOLT-13	GDSC2; CTRP2	2.9705	4.6964	2.9397	20.5821
KE-37	GDSC1; GDSC2; CTRP2	3.0009	5.387	2.8766	20.7019
KG-1	GDSC1; GDSC2; CCLE	3.0074	4.937	2.0377	5.0563
SU-DHL-16	GDSC1; GDSC2	3.008	4.2671	2.5676	5.5746
RC-K8	GDSC1; GDSC2	3.0153	4.31	0.582	0.1903
KY821	GDSC1; GDSC2	3.039	4.3375	0.5811	0.1852
MHH-PREB-1	GDSC1; GDSC2	3.0622	4.5471	0.5158	0.3134
TUR	GDSC1; GDSC2	3.0638	4.6347	0.4848	0.3893
L-540	GDSC1; GDSC2; CTRP2	3.0995	4.2572	3.0956	19.6323
Farage	GDSC1; GDSC2	3.121	5.2892	2.1662	7.649
ALL-SIL	GDSC1; GDSC2; CTRP2; CCLE	3.1389	5.3016	3.041	19.691
WSU-NHL	GDSC1; GDSC2	3.1452	5.2113	0.3014	0.9177
BC-3	GDSC1; GDSC2	3.1475	4.3621	2.6502	4.6235
BONNA-12	GDSC2	3.1504	6.1619	1.7566	10.4103
MN-60	GDSC1; GDSC2	3.1604	5.085	0.3564	0.7162
DG-75	GDSC1; GDSC2	3.176	4.99	0.3987	0.5734
VL51	GDSC1; GDSC2	3.2037	5.0926	0.3716	0.6402
ARH-77	GDSC1; GDSC2	3.2594	5.0138	0.4233	0.4596
ML-2	GDSC1; GDSC2	3.2849	4.7766	0.5178	0.2313
EM-2	GDSC1; GDSC2; CTRP2; CCLE	3.3127	5.4292	3.2059	18.5645
MOLM-6	CTRP2	3.3253	5.4189	3.2214	18.4706
Jurkat	GDSC2; CTRP2; CCLE	3.3267	6.0947	3.0646	19.0238
OCI-Ly7	GDSC2	3.33	5.3837	2.2978	6.4606
SET-2	CTRP2	3.3711	5.6762	3.2186	18.336
LC4-1	GDSC1; GDSC2	3.3756	5.315	0.3588	0.581
Mino	CTRP2; CCLE	3.4138	6.717	2.9653	19.1278
RPMI-8866	GDSC1	3.4373	5.1705	0.4355	0.4388
DoHH2	GDSC1; GDSC2; CCLE	3.5145	5.0164	2.6294	3.2111
SKM-1	GDSC1; GDSC2; CTRP2	3.5284	5.1354	3.483	16.9155
KE-97	CTRP2; CCLE	3.5462	6.9924	3.011	18.5737
DB	GDSC1; GDSC2; CTRP2	3.5577	6.7482	3.1103	18.1695
WSU-DLCL2	GDSC1; GDSC2; CTRP2	3.558	6.1092	3.313	17.4236
Ki-JK	CTRP2	3.5936	5.5998	3.4767	16.7293
NU-DHL-1	CTRP2	3.598	6.8567	3.1157	18.0328
Kasumi-2	CTRP2; CCLE	3.6144	6.5068	3.2532	17.4739
Karpas-299	GDSC1; GDSC2; CTRP2; CCLE	3.688	4.991	3.6661	15.7725
MEG-01	GDSC1; GDSC2; CCLE	3.6882	6.5883	1.742	5.1404
GR-ST	GDSC1; GDSC2	3.7394	5.8163	0.3191	0.509
DEL	GDSC1; GDSC2; CTRP2; CCLE	3.773	5.6598	3.659	15.5246
P31/FUJ	GDSC1; GDSC2; CTRP2; CCLE	3.7786	6.616	3.3949	16.4673
SU-DHL-10	GDSC2; CTRP2; CCLE	3.7922	5.7678	3.6562	15.4745
NKM-1	GDSC1; GDSC2	3.7988	5.7704	0.3584	0.3895
Daudi	GDSC1; GDSC2; CTRP2	3.8106	6.5169	3.4629	16.1212
RPMI-8402	GDSC1; GDSC2; CTRP2; CCLE	3.8351	6.0682	3.6268	15.448
MEC-1	CCLE	3.8715	6.3794	1.9698	3.7496
CML-T1	GDSC2; CTRP2	3.9431	5.8097	3.8108	14.4569
A4/Fukuda	GDSC1; GDSC2; CTRP2	3.9493	6.4928	3.6215	15.1266
SU-DHL-6	GDSC1; GDSC2; CTRP2; CCLE	3.9546	6.2438	3.7063	14.799
MY-M12	GDSC1; GDSC2	3.9854	7.2565	1.8765	7.1295
ROS-50	GDSC1; GDSC2	4.0162	6.3874	2.3222	4.415
WIL2 NS	GDSC1; GDSC2	4.0383	11.8195	-2.1357	11.6701
BC-1	GDSC1; GDSC2	4.0842	5.7108	0.4812	0.1143
HEL	GDSC1; GDSC2; CTRP2	4.0896	7.392	3.4361	15.4331
KMS-20	CTRP2	4.0905	8.3188	3.0418	16.9659
CRO-AP2	GDSC2	4.0949	6.8403	2.1579	5.4007
EB1	CTRP2; CCLE	4.1277	6.8688	3.6813	14.3885
RS4;11	GDSC1; GDSC2; CTRP2	4.1341	7.5915	3.4004	15.4505
L-428	GDSC1; GDSC2; CTRP2; CCLE	4.1362	7.4667	3.4545	15.2349
RPMI-8226	GDSC1; GDSC2; CTRP2	4.1394	6.7627	3.7329	14.1601
HDLM-2	GDSC1; GDSC2; CTRP2	4.1485	8.4286	3.0521	16.7748
Ci-1	CCLE	4.2402	5.2178	2.6781	0.2283
PL-21	GDSC1; GDSC2	4.2882	6.5426	2.428	3.2729
BL-41	GDSC1; GDSC2; CCLE	4.2971	7.4135	1.7578	3.9937
NALM-6	GDSC1; GDSC2; CTRP2	4.3026	6.7407	3.9164	13.0019
M-07e	CTRP2	4.3202	11.1178	1.9585	20.5407
KMS-12-BM	GDSC2; CTRP2; CCLE	4.4103	7.2166	3.8453	12.9747
RCH-ACV	GDSC2; CTRP2	4.4309	7.7147	3.656	13.6599
GDM-1	GDSC1; GDSC2; CTRP2	4.4396	6.8284	4.0304	12.1818
PF-382	GDSC1; GDSC2; CTRP2	4.4623	7.2648	3.8801	12.6987
F-36P	CTRP2; CCLE	4.4842	9.8418	2.7282	17.2094
NK-92MI	GDSC1; GDSC2	4.5175	10.0547	0.8925	11.5609
KCL-22	GDSC1; GDSC2; CTRP2; CCLE	4.5216	7.1123	4.0051	12.0526
KMS-34	CTRP2; CCLE	4.53	6.7795	4.1456	11.4891
U-698-M	GDSC1; GDSC2	4.5492	12.8482	-2.2921	11.458
SUP-B15	GDSC1; GDSC2; CTRP2	4.5749	6.8848	4.1526	11.337
RPMI-6666	GDSC1; GDSC2; CTRP2	4.5821	7.6648	3.8333	12.5648
BDCM	CCLE	4.6384	6.9801	2.1525	1.782
OCI-Ly19	GDSC1; GDSC2; CTRP2	4.7096	8.3501	3.6517	12.9669
OCI-Ly3	CTRP2	4.7437	7.3771	4.125	10.9893
CMK	CTRP2	4.7491	7.3323	4.15	10.8763
SU-DHL-1	GDSC1; GDSC2; CTRP2	4.7537	6.5299	4.4787	9.5924
MHH-CALL-3	CTRP2	4.7916	10.772	2.5697	17.1025
Ri-1	CTRP2	4.7999	8.3795	3.7273	12.4393
QIMR-WIL	GDSC1; GDSC2	4.8048	9.302	1.4592	7.7729
Reh	GDSC1; GDSC2; CTRP2; CCLE	4.8136	7.3534	4.2074	10.4807
SIG-M5	GDSC1; GDSC2; CTRP2; CCLE	4.8284	8.2843	3.7998	12.0763
MHH-CALL-4	GDSC2; CTRP2	4.8504	7.9466	3.978	11.3027
Toledo	CCLE	4.9249	6.88	2.3335	0.8316
Hs 611.T	CTRP2	4.9593	8.5567	3.7993	11.7613
JM-1	CCLE	4.9651	6.5025	2.4942	0.3519
A3/Kawakami	GDSC1; GDSC2; CTRP2	4.9654	9.1413	3.5252	12.8655
HuT 78	CTRP2; CCLE	4.9976	10.8683	2.7128	16.0688
SUP-M2	GDSC1; GDSC2; CTRP2; CCLE	5.0129	6.0903	4.9058	7.2483
SUP-T1	GDSC1; GDSC2; CTRP2; CCLE	5.044	7.7724	4.2511	9.7205
P12-Ichikawa	GDSC2; CTRP2; CCLE	5.0482	8.4119	3.9542	10.9175
OCI-AML-2	GDSC1; GDSC2; CTRP2; CCLE	5.055	7.4678	4.402	9.0853
MOTN-1	CTRP2	5.0921	8.3119	4.0443	10.4452
HPB-ALL	CTRP2	5.098	7.4838	4.4379	8.8332
Kasumi-1	GDSC1; GDSC2; CTRP2	5.1016	7.1698	4.5831	8.2431
KM-H2	GDSC1; GDSC2; CTRP2	5.1114	8.7184	3.8679	11.1222
EHEB	GDSC1; CTRP2	5.1157	9.0074	3.7323	11.6691
EB2	GDSC1; GDSC2; CCLE	5.1164	7.5748	2.1431	1.3137
KMS-11	GDSC2; CTRP2; CCLE	5.2371	7.9139	4.3739	8.7524
SU-DHL-8	GDSC1; GDSC2; CTRP2; CCLE	5.2621	8.0964	4.3109	8.9516
HH [Human lymphoma]	GDSC1; GDSC2; CTRP2; CCLE	5.3436	8.7195	4.0857	9.6927
SU-DHL-4	GDSC1; GDSC2; CTRP2; CCLE	5.3474	8.8722	4.0146	9.9783
K-562	GDSC1; GDSC2; CTRP2	5.3549	8.2885	4.3063	8.7551
Namalwa	GDSC1; GDSC2; CTRP2	5.3796	8.7596	4.0995	9.5549
TALL-1 [Human adult T-ALL]	GDSC2; CTRP2	5.4558	9.3417	3.8828	10.2863
U-937	CTRP2; CCLE	5.467	8.6273	4.245	8.7569
KHM-1B	CTRP2; CCLE	5.4782	8.9053	4.1184	9.2582
MC116	GDSC1; GDSC2; CTRP2; CCLE	5.4873	9.9294	3.6201	11.3083
OPM-2	GDSC1; GDSC2; CTRP2; CCLE	5.537	8.1644	4.5366	7.3902
NB4	GDSC1; GDSC2; CTRP2	5.5696	8.8173	4.2448	8.5332
U266B1	GDSC1; GDSC2; CTRP2	5.6071	10.5989	3.3932	11.9927
MJ	CCLE	5.631	7.8646	2.2579	0.6327
PL21	CTRP2	5.7969	9.3635	4.1743	8.3505
SUP-HD1	GDSC1; GDSC2; CTRP2	5.8149	7.8936	4.9222	5.1796
CA46	GDSC1; GDSC2; CTRP2	5.892	9.1822	4.3468	7.4349
JeKo-1	GDSC2; CTRP2	6.0371	10.0761	4.0225	8.5095
L-363	GDSC1; GDSC2; CTRP2; CCLE	6.0689	9.9436	4.1152	8.0598
KO52	CTRP2; CCLE	6.1637	10.2341	4.0481	8.1601
HEL 92.1.7	CTRP2; CCLE	6.1822	9.9616	4.1994	7.4913
MOLP-8	GDSC1; GDSC2; CTRP2; CCLE	6.2007	7.8551	5.2658	2.9834
LP-1	GDSC1; GDSC2; CTRP2; CCLE	6.2105	8.7083	4.8482	4.7167
KMS-21-BM	CTRP2	6.2178	8.4562	4.9798	4.1514
Karpas-422	GDSC1; GDSC2; CTRP2; CCLE	6.2262	8.949	4.7407	5.1389
HL-60	GDSC1; GDSC2; CTRP2	6.3247	9.0621	4.7623	4.8718
HuNS1	CTRP2	6.3345	10.008	4.2989	6.7948
AML-193	CTRP2	6.4178	13.4536	2.6462	13.4053
OCI-M1	GDSC1; GDSC2; CTRP2	6.4879	8.1211	5.3484	2.1723
ST486	GDSC1; GDSC2; CTRP2	6.5496	9.5417	4.6968	4.7607
HD-MY-Z	CTRP2; CCLE	6.5631	11.1549	3.9075	8.0211
KMS-18	CTRP2	6.5766	8.9565	5.0045	3.4446
TF-1	CTRP2	6.6224	10.4734	4.2912	6.3247
OCI-AML-3	GDSC1; GDSC2; CTRP2	6.6449	9.2233	4.9233	3.6719
KMS-28BM	CTRP2	6.6626	9.9157	4.5967	4.9906
AMO1	GDSC1; GDSC2; CTRP2; CCLE	6.6944	9.2332	4.9539	3.4711
OCI-Ly10	CTRP2; CCLE	6.8401	10.1087	4.6312	4.5688
SUP-T11	CTRP2	6.9082	9.8572	4.8011	3.7754
MM1.S	GDSC2; CTRP2	6.9425	9.4587	5.0152	2.8685
KMS-27	CTRP2	6.9615	8.9795	5.2525	1.9193
DND-41	GDSC1; GDSC2; CTRP2	7.005	12.1191	3.7657	7.8599
SR	GDSC1; GDSC2; CTRP2	7.1295	9.9891	4.8865	3.128
HT	GDSC1; GDSC2; CTRP2; CCLE	7.1452	9.1928	5.2654	1.6617
THP-1	GDSC1; GDSC2; CTRP2	7.186	9.8289	4.9978	2.622
RL	GDSC1; GDSC2; CTRP2	7.2925	8.7597	5.5319	0.6382
Mono-Mac-6	GDSC1; GDSC2; CTRP2	7.2979	12.9674	3.5638	8.2107
BL-70	CTRP2; CCLE	7.3383	8.4965	5.6569	0.2894
EJM	GDSC1; GDSC2; CTRP2	7.3609	9.9153	5.0649	2.1634
MOLP-2	CTRP2	7.4024	11.8163	4.1968	5.4995
Granta-519	GDSC1; GDSC2; CTRP2; CCLE	7.4035	9.4252	5.3071	1.2605
P3HR-1	CTRP2; CCLE	7.5477	9.2498	5.4537	0.6925
OCI-AML-5	GDSC1; CTRP2; CCLE	7.7602	14.7587	3.0212	9.6429
Karpas-620	GDSC2; CTRP2; CCLE	7.9097	9.4207	5.5453	0.2945
SK-MM-2	GDSC1; GDSC2; CTRP2; CCLE	7.9404	9.5445	5.5117	0.3494
Raji	GDSC1; GDSC2; CTRP2; CCLE	7.9938	9.498	5.5503	0.2571
ME1	CTRP2	8.2053	11.3786	4.89	1.9445
NCI-H929	GDSC2; CTRP2	8.2822	9.7277	5.5775	0.1437
KMM-1	CTRP2; CCLE	8.4599	10.7006	5.2909	0.6079
JJN-3	GDSC1; GDSC2; CTRP2	9.4554	18.9609	2.1597	10.3944

Cancer Drug Sensitivity Data Curated from 28 Cell Line(s) in Oesophagus Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
TE15	CTRP2	2.087	8.9767	0.6803	30.9654
TE8	CTRP2	5.2933	10.7358	3.0467	14.0772
OE21	GDSC2; CTRP2; CCLE	-0.598	5.0837	-0.9667	44.8601
T.T	GDSC2	0.4937	6.7511	-2.3076	21.4485
TE-15	GDSC1; CCLE	0.5656	3.9778	0.0242	23.398
KYSE-140	GDSC2; CTRP2; CCLE	0.6941	5.1034	0.4329	36.4346
KYSE-270	GDSC2	1.4844	8.7331	-2.4706	19.2402
TE-11	GDSC2; CTRP2; CCLE	1.5061	6.214	1.0443	31.7488
TE-14	CTRP2	2.4301	9.7629	0.7043	29.8433
TE-6	GDSC1; GDSC2; CTRP2	2.7902	10.6198	0.6908	28.8282
TE-4	GDSC2; CTRP2	2.9964	7.3682	2.2816	22.8676
KYSE-410	GDSC2; CTRP2; CCLE	3.0274	7.9275	2.098	23.4474
TE-9	GDSC1; GDSC2; CTRP2; CCLE	4.4872	9.6997	2.7988	16.9244
COLO 680N	GDSC2; CTRP2	4.7312	12.7927	1.5218	21.1286
TE-10	GDSC1; GDSC2; CTRP2	4.8474	10.7646	2.6252	16.7567
KYSE-70	GDSC2; CTRP2; CCLE	5.0182	9.3179	3.4898	12.8876
TE-5	GDSC1; GDSC2; CTRP2; CCLE	5.056	9.1168	3.6228	12.256
TE-8	GDSC1; GDSC2	5.2452	14.8495	-2.7876	12.4172
KYSE-180	GDSC2; CTRP2; CCLE	5.2504	13.2751	1.7478	19.1623
KYSE-150	GDSC2; CTRP2; CCLE	5.5857	9.8272	3.7583	10.526
KYSE-520	GDSC2; CTRP2; CCLE	5.7343	13.3698	2.1202	16.7686
OE33	GDSC2; CTRP2; CCLE	5.9829	10.7746	3.6279	10.2615
EC-GI-10	GDSC1; GDSC2; CTRP2	6.0617	13.526	2.318	15.36
OE19	GDSC2; CTRP2	6.3668	11.8029	3.4292	10.3523
TE-1	GDSC1; GDSC2; CTRP2; CCLE	7.0033	16.1174	1.783	15.5627
KYSE-510	GDSC2; CTRP2; CCLE	7.7245	15.3583	2.7026	10.9284
KYSE-30	CTRP2; CCLE	9.1539	22.7661	0.1121	17.3787
KYSE-450	GDSC2; CTRP2; CCLE	10.3642	27.8757	-1.5141	19.8404

Cancer Drug Sensitivity Data Curated from 44 Cell Line(s) in Pancreas Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
N2a-PK1	CTRP2	7.673	16.3204	2.1924	12.9268
KCI-MOH1	CCLE	1.2737	4.2224	0.6833	17.6304
HuP-T4	GDSC2; CTRP2; CCLE	1.7282	6.7363	1.1284	30.7457
PK-1	CCLE	3.2129	7.0418	1.1537	9.4708
L3.3	CTRP2; CCLE	3.6123	9.8968	1.8457	22.7489
PL45	CCLE	3.9004	7.2217	1.5843	5.6962
BxPC-3	GDSC2; CTRP2; CCLE	4.1981	9.5899	2.5688	18.5361
SUIT-2	GDSC2; CTRP2; CCLE	4.3374	7.8207	3.5136	14.4665
SNU-213	CTRP2	4.3813	10.9111	2.1163	19.808
KP-1NL	CCLE	4.7479	7.5765	1.9519	2.5304
KP-3	GDSC2; CTRP2; CCLE	4.759	8.5192	3.6217	12.9665
PaTu 8988s	CTRP2	4.9067	16.0199	0.0795	25.256
Hs 766T	GDSC2; CTRP2; CCLE	4.9162	11.8578	2.1512	18.4225
KP-1N	GDSC2; CCLE	5.1291	8.468	2.0533	3.2857
SW1990	GDSC2; CTRP2; CCLE	5.2716	9.6373	3.5693	11.9877
PL4	GDSC2	5.3543	7.8498	2.4436	1.4279
Panc 05.04	CTRP2	5.4274	13.8464	1.618	19.2422
HPAF-II	GDSC2; CTRP2; CCLE	5.5779	12.706	2.3173	16.3477
MZ-PC-1	GDSC1; GDSC2	5.7198	12.9125	0.3478	11.8036
KP-2	GDSC2; CCLE	5.7823	10.596	1.4732	5.0005
Panc 08.13	GDSC2; CTRP2	6.0704	12.9555	2.6105	14.2125
MIA PaCa-2	GDSC2; CTRP2; CCLE	6.336	9.4759	4.5652	5.677
Panc 03.27	GDSC2; CTRP2; CCLE	6.435	16.5111	1.1328	18.8586
QGP-1	GDSC2; CTRP2; CCLE	6.4352	11.7471	3.5118	9.887
Panc 02.03	GDSC2; CTRP2; CCLE	6.5035	12.0863	3.3971	10.2342
Capan-1	GDSC2; CTRP2	6.5942	12.6273	3.1992	10.8765
PK-59	CTRP2; CCLE	6.6728	11.4757	3.833	8.1393
KP-4	GDSC2; CTRP2; CCLE	6.6936	10.3963	4.383	5.8251
HPAC	GDSC2; CTRP2; CCLE	6.9482	19.3404	0.1338	20.9821
TCC-Pan2	CTRP2	7.0294	10.4091	4.6184	4.3383
SU.86.86	GDSC2; CTRP2; CCLE	7.1215	14.2336	2.8092	11.5072
Capan-2	GDSC2; CTRP2; CCLE	7.1317	14.872	2.5008	12.6821
AsPC-1	GDSC2; CTRP2; CCLE	7.2626	13.2779	3.3858	8.9834
PK-45H	CTRP2; CCLE	7.3788	9.9392	5.0647	2.1445
YAPC	GDSC2; CTRP2	7.495	14.6096	2.9023	10.524
DAN-G	GDSC2; CTRP2	7.5183	21.9642	-0.723	22.294
CFPAC-1	GDSC2; CTRP2	7.6833	20.9195	-0.0753	20.2749
PSN1	GDSC1; GDSC2; CTRP2; CCLE	7.9916	11.7538	4.6029	3.1725
Panc 10.05	GDSC2; CTRP2; CCLE	8.0582	16.3182	2.4737	11.2706
PaTu 8902	GDSC2; CTRP2; CCLE	8.0775	13.2317	3.9709	5.4729
SNU-410	CTRP2	8.1029	17.4829	1.9368	13.1583
HuP-T3	GDSC2; CTRP2; CCLE	8.5349	15.887	3.0119	8.5461
Panc 04.03	GDSC2; CTRP2; CCLE	10.1311	23.7504	0.3224	15.3605
PaTu 8988t	GDSC2; CTRP2	12.8278	29.0485	-0.4155	14.0085

Cancer Drug Sensitivity Data Curated from 79 Cell Line(s) in Skin Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SH4	CTRP2	4.651	13.1306	1.2822	22.1359
A-388	GDSC1; GDSC2	0.6981	6.9316	-0.9586	32.8362
A-431	GDSC2	0.8291	5.6485	-0.2585	30.4248
CHL-1	GDSC2; CCLE	1.8511	4.4148	1.2	12.6968
M14	GDSC2	1.8525	7.6638	-1.6508	14.0221
WM278	GDSC2	2.1816	11.727	-3.4134	21.463
HMV-II	GDSC2	2.194	5.8753	-0.5287	6.6872
GAK	GDSC2	2.5275	4.0673	0.4757	0.7533
WM35	GDSC2	2.5519	6.9958	-0.8241	7.6717
COLO 741	CCLE	2.6545	6.4276	0.9904	11.7602
IST-MEL1	GDSC1; GDSC2	2.7312	4.7038	0.3147	1.223
SH-4	GDSC1; GDSC2	2.8891	4.9128	0.3042	1.1181
COLO 679	GDSC2; CCLE	3.1163	4.5456	2.3218	3.3044
G-361	GDSC2; CTRP2; CCLE	3.136	6.0944	2.8566	20.354
MZ-MEL-2	GDSC1; GDSC2	3.364	5.4821	2.2767	6.2716
WM1552C	GDSC2	3.3932	5.2517	0.3891	0.4869
G-mel	GDSC2	3.6297	6.2709	2.0955	6.9131
MZ-MEL-7	GDSC1; GDSC2	3.7861	8.134	1.2909	11.0896
DJM-1	GDSC1; GDSC2	3.8318	11.1945	-0.1979	18.8699
451Lu	GDSC2	4.0329	5.95	2.5427	3.2089
WM1799	CTRP2; CCLE	4.4618	8.6394	3.2717	15.1075
COLO 783	GDSC2	4.5738	6.4811	2.6232	1.8487
VMRC-MELG	GDSC2	4.8294	12.2323	0.0521	15.6063
MMAc-SF	GDSC1; GDSC2	4.8317	7.4204	2.3521	2.796
CP66-MEL	GDSC1; GDSC2	4.9259	11.6153	0.424	13.1057
WM88	CTRP2; CCLE	4.9716	7.6962	4.2141	10.0497
Hs 938.T	GDSC2; CCLE	4.9828	6.9739	2.6241	1.1239
WT2-iPS	GDSC2; CCLE	5.1647	7.2734	2.5888	1.0685
CP50-MEL-B	GDSC2	5.349	14.1823	-0.5256	17.0685
IPC-298	GDSC2; CTRP2; CCLE	5.4092	10.4483	3.293	12.8235
Mel Ho	GDSC2; CTRP2; CCLE	5.4296	8.0927	4.4716	7.9016
SF8657	CCLE	5.4647	7.5275	2.3159	0.5637
COLO 792	GDSC2; CTRP2	5.492	9.0338	4.0676	9.4393
WM793	GDSC2; CTRP2; CCLE	5.5629	9.3903	3.955	9.7557
Hs 934.T	CTRP2	5.6801	11.3596	3.0774	13.1332
LOX-IMVI	GDSC1; GDSC2; CTRP2; CCLE	5.7033	9.395	4.077	8.9505
LB2518-MEL	GDSC1; GDSC2	5.7631	15.0109	-0.6343	16.2104
Hs 695T	CCLE	5.917	9.0395	1.9265	1.474
RPMI-7951	GDSC2; CTRP2; CCLE	5.9604	9.7386	4.1268	8.2218
MeWo	GDSC2; CTRP2; CCLE	5.9834	11.1974	3.4169	11.1338
WM115	GDSC2; CTRP2; CCLE	5.9907	9.6731	4.1851	7.9179
Hs 944.T	CTRP2; CCLE	6.2976	10.0768	4.2352	7.1284
A2058	GDSC2; CTRP2; CCLE	6.3257	7.5294	5.5212	1.7119
COLO 800	GDSC1; GDSC2; CTRP2	6.3624	12.2857	3.1847	11.3597
Hs 940.T	GDSC2; CTRP2	6.3974	11.9635	3.3736	10.5239
HMCB	CTRP2; CCLE	6.4247	10.2417	4.2537	6.8227
Hs 294T	CTRP2; CCLE	6.4249	10.3188	4.2154	6.9822
IGR-39	CTRP2; CCLE	6.4971	10.0954	4.3827	6.1574
IGR-1	GDSC2; CTRP2	6.5487	12.1556	3.3983	10.1478
Hs 839.T	CTRP2	6.5729	10.3213	4.3288	6.2523
RVH-421	GDSC2; CTRP2; CCLE	6.6049	13.2169	2.9138	12.003
Hs 852.T	CTRP2; CCLE	6.6635	11.2227	3.9513	7.6656
K029AX	CTRP2; CCLE	6.6945	10.1831	4.4887	5.3859
SK-MEL-3	GDSC2; CTRP2	6.6958	12.6326	3.2762	10.3832
CJM [Human melanoma]	CTRP2	6.8161	9.3324	4.9906	3.1427
SK-MEL-24	GDSC2; CTRP2; CCLE	6.8662	11.2296	4.1007	6.7096
SK-MEL-2	GDSC1; GDSC2; CTRP2; CCLE	6.8756	8.0089	5.6378	0.6254
WM983B	CTRP2; CCLE	6.996	10.8001	4.4054	5.254
Hs 688(A).T	CTRP2	7.0024	11.1908	4.2193	6.0053
UACC-257	GDSC1; GDSC2; CTRP2; CCLE	7.0207	8.5538	5.4796	1.0253
SK-MEL-30	GDSC2; CTRP2; CCLE	7.0771	10.1828	4.7597	3.7018
HT-144	GDSC1; GDSC2; CTRP2; CCLE	7.1423	12.2281	3.8129	7.4467
MDA-MB-435S	CTRP2; CCLE	7.173	10.444	4.6992	3.8108
SK-MEL-1	GDSC1; GDSC2; CTRP2	7.1879	10.9966	4.4444	4.8114
Hs 895.T	CTRP2; CCLE	7.2216	11.3717	4.2866	5.3996
Hs 936.T	CTRP2; CCLE	7.418	10.473	4.8432	2.9321
SK-MEL-5	GDSC2; CTRP2; CCLE	7.753	12.5496	4.0818	5.469
WM266-4	CTRP2; CCLE	7.8155	12.5112	4.1411	5.1526
UACC-62	GDSC2; CTRP2; CCLE	8.0755	15.742	2.7663	10.1427
COLO 829	GDSC1; GDSC2; CTRP2	8.1447	16.5264	2.4339	11.2857
SK-MEL-31	GDSC2; CTRP2; CCLE	8.1942	15.1632	3.1284	8.5821
IGR-37	GDSC2; CTRP2; CCLE	8.378	14.3868	3.6208	6.4333
A-375	GDSC2; CTRP2; CCLE	8.4495	14.759	3.4915	6.835
Malme-3M	CTRP2; CCLE	8.7146	20.3625	0.9703	15.4581
LB373-MEL-D	GDSC1; GDSC2	9.1451	26.0966	-3.6544	20.1074
A101D	GDSC1; GDSC2; CTRP2	9.7072	18.4496	2.5639	8.645
Mel JuSo	GDSC2; CTRP2	11.443	22.3478	1.8315	9.0651
SK-MEL-28	GDSC2; CTRP2	12.5052	30.5877	-1.3506	16.7076
EquiPSC Line K2	GDSC2	3.3709	8.463	0.7921	15.5691

Cancer Drug Sensitivity Data Curated from 11 Cell Line(s) in Aero Dig Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
TE-12	GDSC1; GDSC2	-2.9348	13.4187	-7.5651	53.5342
KYAE-1	GDSC2	1.2988	5.7915	-1.1516	12.6433
KYSE-50	GDSC2	1.7372	6.9503	-1.3853	12.8301
KYSE-220	GDSC2	1.7729	9.4212	-2.5851	18.9869
ESO-26	GDSC2	2.0844	4.6489	-0.0193	3.8974
OACM5.1 C	GDSC2	2.3988	4.7547	0.1204	2.5823
FLO-1	GDSC2	2.5053	7.3667	-1.033	8.9738
OACP4 C	GDSC2	2.7317	10.6963	-2.4916	16.1371
ESO-51	GDSC2	3.0566	5.1559	0.2838	1.0538
SK-GT-4	GDSC2	4.0146	14.7544	-3.5557	17.8383
HCE-4	GDSC2	4.9207	7.0917	2.5436	1.7937

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
COLO 684	GDSC1; GDSC2	2.6713	4.8117	0.2409	1.6167

Cancer Drug Sensitivity Data Curated from 36 Cell Line(s) in Autonomic Ganglia Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SJNB-6	GDSC1; GDSC2	1.3824	3.0985	1.2618	19.3969
SJNB-10	GDSC1; GDSC2	2.0402	4.6478	-0.0469	4.1431
NB(TU)1	GDSC1; GDSC2	2.1642	5.0611	-0.1617	4.5762
SJNB-13	GDSC1; GDSC2	2.3025	5.3668	-0.2169	4.6345
IMR-5	GDSC1; GDSC2	2.3849	4.1457	0.3763	1.3148
CHP-134	GDSC2	2.6866	5.1126	0.1209	2.1763
SK-N-BE(2)-M17	GDSC1; GDSC2	2.8165	6.8713	-0.5953	5.8488
TGW	GDSC1; GDSC2	3.1255	4.6806	0.4921	0.3441
SJNB-14	GDSC1; GDSC2	3.2629	4.9723	0.4398	0.4147
NB69	GDSC1; GDSC2	3.3087	8.7567	-1.1646	8.0916
SJNB-7	GDSC1; GDSC2	3.5898	5.1872	0.4858	0.2041
GOTO	GDSC1; GDSC2	3.6497	6.1297	0.165	1.0339
NH-12	GDSC1; GDSC2	3.7605	5.5478	0.4226	0.2697
SK-N-MC-IXC	GDSC2	3.8258	6.2551	2.2511	5.4469
SJNB-12	GDSC1; GDSC2	3.834	5.7936	0.3634	0.3655
LA-N-6	GDSC1; GDSC2	3.9264	5.8948	2.4978	3.5723
KP-N-RT-BM-1	GDSC2	3.9945	7.0547	1.982	6.7103
SJNB-17	GDSC1; GDSC2	4.1847	9.4454	0.9461	12.0572
IMR-32	CCLE	4.2797	5.2961	2.665	0.2424
SiMa	GDSC1; GDSC2; CCLE	4.3847	6.4359	2.2526	1.5954
KP-N-SI9s	CTRP2; CCLE	4.4948	7.6056	3.7692	13.0463
GI-ME-N	GDSC1; GDSC2	4.5053	14.9229	-3.3014	15.8718
Kelly	GDSC1; GDSC2; CTRP2; CCLE	4.7831	6.8168	4.4004	9.8085
NB1	GDSC1; GDSC2; CTRP2	4.9329	6.7582	4.5824	8.6947
SK-N-BE(2)	CTRP2; CCLE	5.4312	11.4927	2.7938	14.7958
MHH-NB-11	GDSC1; GDSC2; CTRP2	5.5174	10.3496	3.4383	11.9957
CHP-212	GDSC2; CTRP2; CCLE	5.5304	8.4295	4.4004	7.9706
SK-N-FI	GDSC1; GDSC2; CTRP2; CCLE	5.5899	8.4603	4.4396	7.6772
KP-N-YS	GDSC1; GDSC2	5.8561	7.7576	2.6992	0.4369
SK-N-SH	GDSC2; CTRP2; CCLE	6.0393	9.1192	4.5027	6.4899
NH-6	CTRP2	6.6556	9.7757	4.6604	4.7385
SK-N-DZ	GDSC1; GDSC2; CTRP2; CCLE	6.7492	11.9832	3.6399	8.8039
CHP-126	GDSC1; GDSC2; CTRP2	6.8953	11.3579	4.0591	6.8338
SJNB-5	GDSC1; GDSC2	7.0028	17.0767	-0.7828	14.3975
SK-N-AS	GDSC2; CTRP2; CCLE	7.4891	10.943	4.6689	3.5152
KP-N-YN	GDSC1; GDSC2; CTRP2	7.8919	10.0232	5.3024	0.8968

Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Biliary Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SNU-1079	CTRP2	-1.2395	2.4396	-1.2821	48.5592
SNU-478	CTRP2	1.7376	9.5206	0.0885	33.6967
SNU-308	CTRP2	1.9088	7.0182	1.232	29.8264
HuCC-T1	GDSC2; CTRP2; CCLE	3.7178	11.3111	1.2878	24.41
SNU-1196	CTRP2	4.9579	12.7483	1.7489	19.8074
HuH-28	CTRP2	6.2586	10.9949	3.7453	9.2462
SNU-869	CTRP2	11.9584	26.8967	0.0387	13.8111

Cancer Drug Sensitivity Data Curated from 92 Cell Line(s) in Breast Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
MDA-MB-175-VII	GDSC2; CCLE	0.6366	4.103	0.0536	22.3827
HCC2157	GDSC1; GDSC2	1.744	5.2044	-0.519	7.6407
UACC-893	GDSC2	2.1982	5.0239	1.4178	15.7643
DU4475	GDSC1; GDSC2	2.2854	3.7157	0.5051	0.8491
CAL-85-1	GDSC2; CTRP2; CCLE	2.2889	9.7039	0.5841	30.6212
Evsa-T	GDSC1; GDSC2	2.2978	3.7476	0.498	0.867
MFM-223	GDSC1; GDSC2	2.4134	4.2531	0.3456	1.4253
MRK-nu-1	GDSC1; GDSC2	2.7181	4.2808	0.476	0.6104
AU565	GDSC2; CTRP2; CCLE	2.7797	7.0471	2.1648	23.9289
COLO 824	GDSC1; GDSC2	2.9182	5.5252	0.0653	2.1559
MDA-MB-330	GDSC2	3.0718	6.7196	1.4104	12.8025
SK-BR-3	CTRP2; CCLE	3.0912	5.9609	2.8438	20.5368
UACC-812	GDSC1; GDSC2; CCLE	3.1077	4.835	2.1707	4.1192
OCUB-M	GDSC1; GDSC2	3.2375	4.8868	0.4609	0.3729
ZR-75-30	GDSC2; CTRP2; CCLE	3.7562	6.1889	3.5063	16.1233
HCC1954	GDSC2; CTRP2; CCLE	3.8575	8.628	2.6669	19.0332
HCC38	GDSC2	3.8734	5.7099	0.4073	0.2653
BT-474	GDSC1; GDSC2; CTRP2; CCLE	3.9199	6.9	3.4466	15.8663
HCC2218	GDSC1; GDSC2; CTRP2	3.9286	7.1136	3.3754	16.112
HCC1569	GDSC2; CCLE	4.1509	8.2786	1.4959	7.7802
BT-483	GDSC2	4.1653	14.9782	-3.5594	17.5467
HCC70	GDSC2; CCLE	4.2024	9.5293	0.6752	9.548
MDA-MB-415	GDSC2; CCLE	4.2436	6.3571	2.2096	1.9497
MDA-MB-468	GDSC2; CTRP2; CCLE	4.2975	9.4543	2.73	17.661
EFM-19	GDSC2; CCLE	4.3461	6.6935	2.1178	2.2296
HDQ-P1	GDSC2; CTRP2; CCLE	4.3744	14.9146	0.1507	26.2749
MDA-MB-436	GDSC2; CCLE	4.3871	8.3384	1.3795	5.7036
CAL-51	GDSC2; CTRP2	4.7521	8.3397	3.6986	12.6728
HCC1187	GDSC1; GDSC2; CCLE	4.7685	7.1048	2.1667	1.5423
Hs 739.T	CCLE	4.9247	7.1707	2.2165	1.2434
HCC1143	GDSC2; CTRP2	5.4181	10.5863	3.2324	13.0523
Hs 578Bst	CTRP2	5.42	11.2697	2.8948	14.416
EFM-192A	GDSC2; CTRP2	5.4369	9.0747	3.9973	9.8518
MDA-MB-453	GDSC2; CTRP2; CCLE	5.4414	10.8182	3.1381	13.3871
HCC202	CTRP2	5.5329	9.5422	3.8528	10.245
HCC1419	GDSC2; CTRP2	5.5968	9.3968	3.982	9.571
HCC1395	GDSC2; CTRP2; CCLE	5.6856	10.0229	3.7487	10.3573
HCC1599	GDSC1; GDSC2	5.7483	9.9946	1.725	4.6684
CAL-148	GDSC1; GDSC2; CTRP2	6.1121	11.0438	3.6009	10.1227
KPL-1	CTRP2	6.3107	8.4437	5.0588	3.6565
HCC1806	GDSC2; CTRP2; CCLE	6.3612	16.8036	0.9264	19.6747
Hs 578T	GDSC2; CTRP2; CCLE	6.502	9.983	4.4423	5.9006
YMB-1-E	GDSC2	6.513	8.4546	2.6976	0.2364
BT-20	GDSC2; CTRP2; CCLE	6.588	10.7685	4.1187	7.1004
HCC1500	GDSC2; CTRP2	6.6274	11.3156	3.8775	8.0335
JIMT-1	GDSC2; CTRP2	6.7877	13.0378	3.1462	10.7468
CAL-120	GDSC2; CTRP2	7.0653	11.93	3.903	7.2012
MCF-7	GDSC2; CTRP2; CCLE	7.1458	9.5297	5.1117	2.2352
MDA-MB-231	GDSC2; CTRP2	7.1764	11.154	4.3604	5.1675
MDA-MB-361	GDSC2; CTRP2	7.2691	16.1439	1.9754	14.4013
HMC-1-8	CTRP2; CCLE	7.3841	11.16	4.4984	4.3209
HCC1937	GDSC2; CTRP2	7.4925	14.2324	3.0856	9.8101
MDA-MB-157	GDSC2; CTRP2; CCLE	7.6673	12.5079	4.0446	5.7334
T-47D	GDSC2; CTRP2; CCLE	7.714	14.6094	3.061	9.5589
CAMA-1	GDSC2; CTRP2; CCLE	7.883	12.5867	4.1492	5.0322
HCC1428	GDSC2; CTRP2	8.2128	15.6083	2.9267	9.3277
ZR-75-1	CTRP2; CCLE	8.5008	16.7089	2.5945	10.159
BT-549	GDSC2; CTRP2; CCLE	8.5326	10.6456	5.3423	0.4647
BT 239	CTRP2	3.2723	11.2127	0.8985	26.8501
BT 145	CTRP2	3.4258	8.0431	2.4709	20.9459
BT 172	CTRP2	4.0842	11.2634	1.6635	22.1855
BT 416	CTRP2	4.3735	7.8944	3.5185	14.3528
BT 428	CTRP2	4.5544	12.7568	1.3779	22.0378
BT 159	CTRP2	4.7032	14.3809	0.7117	23.8572
BT 271	CTRP2	4.9238	12.752	1.7164	20.0008
BT 245	CTRP2	5.153	8.9969	3.7724	11.4188
BT 139	CTRP2	5.3561	16.0974	0.4334	23.2533
BT 231	CTRP2	5.4202	14.4362	1.3176	20.2983
BT 228	CTRP2	5.8139	13.3278	2.2089	16.2718
BT147	CTRP2	5.8379	11.4469	3.1692	12.4385
BT 330	CTRP2	5.8501	14.5455	1.6308	18.3137
BT 340	CTRP2	6.2513	12.119	3.1777	11.5967
BT 248	CTRP2	6.6211	15.2043	1.9357	15.712
BT 286	CTRP2	6.8975	9.3076	5.0573	2.7626
BT 320	CTRP2	6.9006	12.0778	3.7081	8.2679
BT 359	CTRP2	6.9128	14.8481	2.3437	13.6635
BT164	CTRP2	7.0108	11.4016	4.1223	6.3899
BT 131	CTRP2	7.045	10.7495	4.4645	4.9394
BT 112	CTRP2	7.0737	12.4719	3.6429	8.2493
BT 498	CTRP2	7.1837	8.3707	5.6381	0.4122
BT 187	CTRP2	7.2311	15.5084	2.2614	13.4147
BT 422	CTRP2	7.279	12.6653	3.698	7.6984
BT 482	CTRP2	7.3453	9.1957	5.3753	1.085
BT 444	CTRP2	7.4145	12.0066	4.1134	5.8168
BT 232	CTRP2	7.6616	15.787	2.4463	12.0012
BT 440	CTRP2	7.6659	12.2976	4.144	5.3418
BT 216	CTRP2	7.6674	14.1795	3.2373	8.9389
BT 504	CTRP2	7.7657	13.404	3.6815	7.035
BT 328	CTRP2	7.7986	13.088	3.8555	6.2998
BT 179	CTRP2	8.2444	16.5986	2.4694	11.0022
BT 224	CTRP2	8.5923	14.5685	3.6724	5.9634
BT 333	CTRP2	9.7733	17.2241	3.1717	6.4035

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Tongue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
YD-38	CTRP2	-0.6459	5.1071	-1.024	45.1644

Cancer Drug Sensitivity Data Curated from 69 Cell Line(s) in Central Nervous System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
PFSK-1	GDSC2	1.979	5.2915	-0.3948	6.3475
AM-38	GDSC1; GDSC2	2.4132	4.3537	0.3029	1.6298
LN-405	GDSC2	2.5905	4.7605	0.2214	1.8052
D-263MG	GDSC1; GDSC2	2.9783	4.9822	0.3172	0.9903
SK-MG-1	GDSC2	3.1112	5.1405	0.314	0.8975
KINGS-1	GDSC1; GDSC2	3.1736	5.1583	0.3341	0.7824
D-392MG	GDSC1; GDSC2	3.1905	9.6012	-1.6405	10.869
KS-1 [Human Krukenberg tumour]	GDSC1; GDSC2	3.3393	12.4633	-2.9184	16.6791
MOG-G-UVW	GDSC2	3.3482	5.3687	0.3275	0.6913
D-566MG	GDSC2	3.6294	6.0373	2.2112	6.1867
SNU-466	CTRP2	3.7641	7.0161	3.2363	17.1038
H4	GDSC2; CCLE	3.8242	8.1942	1.0537	8.405
D-336MG	GDSC1; GDSC2	3.9254	6.4652	2.2204	5.2154
Onda 10	GDSC1; GDSC2	4.2091	6.0865	2.5904	2.5093
1321N1	CCLE	4.2346	8.5433	1.1776	7.1695
D-247MG	GDSC1; GDSC2	4.4452	11.2913	0.2303	15.2128
Onda 11	GDSC1; GDSC2	4.644	10.9641	0.5388	13.1591
GI-1	GDSC1; GDSC2; CCLE	4.7268	6.9607	2.2063	1.4279
U-87MG ATCC	GDSC1; GDSC2; CCLE	4.7414	6.2539	2.496	0.441
D-423MG	GDSC2	4.7524	8.7889	1.669	6.9267
M059J	GDSC2; CCLE	5.133	7.6908	2.1035	1.4443
DBTRG-05MG	GDSC2; CTRP2; CCLE	5.2336	9.1591	3.7687	11.2508
NMC-G1	GDSC1; GDSC2; CTRP2	5.3327	10.7328	3.0835	13.8426
KG-1-C	CTRP2	5.3863	9.9745	3.5071	11.9927
KNS-81-FD	GDSC1; GDSC2	5.5598	7.4537	2.6929	0.6004
MOG-G-CCM	GDSC2; CCLE	5.5669	7.7384	2.2789	0.5932
GB-1	GDSC1; GDSC2; CTRP2; CCLE	5.6853	11.2025	3.1603	12.7854
D-502MG	GDSC1; GDSC2	5.6999	21.656	-3.9466	26.9009
SNU-489	CTRP2	5.7422	8.9486	4.3333	7.7973
D-245MG	GDSC2	5.7824	9.9344	1.7712	4.5355
SNB-75	GDSC1; GDSC2; CTRP2	5.7976	11.1508	3.2827	12.056
D283 Med	GDSC1; GDSC2; CTRP2	5.8383	9.6453	4.0694	8.7059
KALS-1	GDSC1; GDSC2; CTRP2; CCLE	5.9621	11.8412	3.0771	12.5652
SNU-626	CTRP2	6.0085	8.0859	4.9935	4.4869
SNU-1105	CTRP2	6.084	9.7302	4.2344	7.5305
SNU-201	CTRP2	6.1808	10.6382	3.8602	8.9132
Daoy	GDSC2; CTRP2; CCLE	6.3008	11.351	3.6016	9.7637
SF539	GDSC1; GDSC2; CTRP2	6.4182	12.733	3.0062	11.9767
KNS-60	CTRP2; CCLE	6.4322	9.2483	4.7531	4.7239
SNU-738	CTRP2	6.4532	10.3205	4.2367	6.8433
SW1088	GDSC2; CTRP2; CCLE	6.4804	10.4911	4.1731	7.0607
KNS-81	CTRP2; CCLE	6.5103	10.1508	4.3654	6.2069
SF126	GDSC1; GDSC2; CTRP2; CCLE	6.5478	9.7187	4.608	5.1328
SF268	GDSC1; GDSC2; CTRP2	6.5731	12.2975	3.3468	10.3144
CAS-1	GDSC1; GDSC2; CTRP2; CCLE	6.6034	8.428	5.2801	2.2803
DK-MG	GDSC2; CTRP2; CCLE	6.6357	11.6015	3.7419	8.5802
TM-31	CTRP2	6.7168	10.1917	4.5009	5.2991
LN-229	GDSC2; CTRP2; CCLE	6.7417	14.251	2.5067	13.3489
YH-13	GDSC2; CTRP2	6.8553	9.4441	4.9636	3.1956
U-118MG	GDSC2; CTRP2; CCLE	6.8833	11.8157	3.8246	7.8183
Hs 683	GDSC2; CTRP2; CCLE	6.9625	9.5012	5.0083	2.8692
M059K	CTRP2	7.0093	8.9801	5.2814	1.7535
42-MG-BA	GDSC2; CTRP2; CCLE	7.0838	12.1394	3.8138	7.5362
ONS-76	GDSC1; GDSC2; CTRP2; CCLE	7.1494	10.2288	4.7859	3.4984
GOS-3	CTRP2	7.1521	11.1425	4.349	5.2493
8-MG-BA	GDSC1; GDSC2; CTRP2; CCLE	7.2196	11.8032	4.0759	6.2567
SF295	GDSC2; CTRP2; CCLE	7.2501	9.5974	5.1437	1.9947
CCF-STTG1	CTRP2	7.3494	8.4772	5.6688	0.2589
GaMG	GDSC2; CTRP2; CCLE	7.4361	11.8395	4.2086	5.404
GMS-10	CTRP2; CCLE	7.5323	10.805	4.7602	3.1113
T98G	GDSC2; CTRP2; CCLE	7.761	12.5682	4.0783	5.472
D-542MG	GDSC1; GDSC2	7.7737	23.4676	-3.3254	21.4713
KNS-42	GDSC1; GDSC2; CTRP2; CCLE	7.785	13.4783	3.659	7.0964
A-172	GDSC2; CTRP2; CCLE	7.8243	12.3921	4.203	4.8988
YKG-1	GDSC2; CTRP2; CCLE	8.1256	14.1448	3.5698	6.9684
Becker	GDSC1; GDSC2; CTRP2	8.2368	15.5931	2.9506	9.2018
SW1783	GDSC2; CTRP2	8.8241	10.5656	5.4832	0.156
LN-18	GDSC2; CTRP2; CCLE	10.9896	22.8648	1.3116	11.2425
U-251MG	GDSC2; CTRP2	12.96	25.8249	1.1501	9.53

Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Digestive System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
TGBC24TKB	GDSC2	1.2012	7.2869	-1.9774	17.5754
TGBC1TKB	GDSC1; GDSC2	2.5835	4.1377	0.473	0.7191
ETK-1	GDSC1; GDSC2	3.4152	12.8829	-3.0688	17.1527

Cancer Drug Sensitivity Data Curated from 24 Cell Line(s) in Endometrium Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
RL95-2	GDSC1; GDSC2; CTRP2; CCLE	2.3542	7.1142	1.6815	26.9213
JHUEM-3	CTRP2	3.1362	6.4113	2.7633	20.6913
JHUEM-2	CTRP2; CCLE	3.1942	4.895	3.1561	19.1169
MFE-280	GDSC2; CCLE	3.4496	6.9563	1.383	7.4928
HEC-1-B	CTRP2; CCLE	3.8514	10.931	1.5978	23.0057
JHUEM-7	CTRP2	4.1949	6.5692	3.8617	13.5166
HEC-251	CTRP2; CCLE	4.1994	9.1437	2.7777	17.7202
AN3-CA	GDSC2; CTRP2; CCLE	4.6337	8.1505	3.6678	13.0917
MFE-296	GDSC2; CTRP2; CCLE	4.8982	9.652	3.2146	14.2851
HEC-151	CTRP2; CCLE	5.0005	13.7405	1.2951	21.2938
TEN	CCLE	5.1108	7.3174	2.2443	0.9946
JHUEM-1	CTRP2	5.1799	9.3131	3.6435	11.8876
HEC-1-A	CTRP2; CCLE	5.244	8.9049	3.9024	10.6754
HEC-59	CTRP2; CCLE	5.6597	9.251	4.1102	8.9029
HEC-6	CTRP2; CCLE	6.1531	10.1974	4.0578	8.1397
ESS-1	GDSC2; CTRP2; CCLE	6.6567	8.5233	5.2706	2.2433
HEC-265	CTRP2; CCLE	6.721	9.4695	4.8578	3.8235
KLE	GDSC2; CTRP2; CCLE	6.9841	12.7379	3.4449	9.2021
EN	GDSC2; CTRP2; CCLE	7.368	9.2152	5.3788	1.0543
EFE-184	CTRP2; CCLE	8.7253	19.8603	1.2232	14.6261
HEC-108	CTRP2	8.8033	19.2804	1.5608	13.3849
MFE-319	GDSC2; CTRP2; CCLE	9.3765	22.9608	0.1767	16.861
HEC-50B	CTRP2	10.6012	29.5635	-2.1678	20.9871
Ishikawa (Heraklio) 02 ER-	CTRP2; CCLE	7.5527	21.236	-0.3339	21.2113

Cancer Drug Sensitivity Data Curated from 40 Cell Line(s) in Kidney Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
LB996-RCC	GDSC1; GDSC2	0.1078	14.3685	-6.4415	35.3925
TK-10	GDSC1; GDSC2	0.4305	5.8276	-1.9035	19.5768
SW13	GDSC2	1.0193	6.0889	-1.5284	15.6485
CAL-54	GDSC2; CTRP2	1.2812	13.0503	-1.932	39.1047
SN12C	GDSC2	2.2424	8.5343	-1.7885	13.7872
A-704	GDSC2	2.2564	9.3708	-2.1901	15.8261
KTCTL-195	GDSC2	2.4676	4.837	0.1225	2.4698
LB1047-RCC	GDSC1; GDSC2	2.7056	9.4679	-0.2787	22.5553
KTCTL-13	GDSC2	3.0598	5.7821	1.8671	9.998
LB2241-RCC	GDSC1; GDSC2	3.2071	16.8112	-3.5186	31.5849
SW156	GDSC2	3.2285	10.7676	-0.4791	22.4527
UO-31	GDSC2; CTRP2	3.2522	10.3905	1.2593	25.7453
KTCTL-140	GDSC2	3.9445	13.6092	-1.3126	23.7754
HA7-RCC	GDSC1; GDSC2	4.1619	10.9776	0.1696	16.2249
KTCTL-21	GDSC2	4.3459	13.6942	-1.0375	21.6547
RXF 393L	GDSC1; GDSC2	4.4627	10.0297	0.8647	11.8403
KTCTL-26A	GDSC2	4.5041	10.8102	0.5115	14.0521
NCC021	GDSC2	4.5419	8.994	1.427	8.7996
KTCTL-1M	GDSC2	4.6025	10.9284	0.526	13.7339
NCC010	GDSC2	5.1608	13.1473	-0.1553	15.8197
ACHN	GDSC2; CTRP2; CCLE	5.1759	14.6301	1.0079	21.8563
TUHR4TKB	CTRP2	5.2368	9.7408	3.4864	12.4063
VMRC-RCW	GDSC2; CTRP2; CCLE	5.4643	8.7381	4.1881	8.9991
Caki-2	CTRP2; CCLE	5.5642	11.8961	2.7093	14.85
BB65-RCC	GDSC1; GDSC2	5.6176	16.2269	-1.3317	19.3048
KMRC-3	CTRP2	5.7796	15.8107	0.9389	20.7966
769-P	GDSC2; CTRP2; CCLE	5.8156	17.3933	0.1782	23.0412
BFTC-909	GDSC2; CTRP2; CCLE	6.3427	10.6689	3.9758	8.1309
OS-RC-2	GDSC1; GDSC2; CTRP2	6.6406	14.8008	2.1526	14.8764
KMRC-1	GDSC2; CTRP2; CCLE	6.6947	11.3173	3.9283	7.7075
A-498	GDSC2; CTRP2	6.8675	10.4551	4.4817	5.1395
786-O	GDSC2; CTRP2; CCLE	7.1318	11.4288	4.1958	5.9025
TUHR10TKB	CTRP2	7.1605	9.7512	5.018	2.5758
Caki-1	GDSC2; CTRP2	7.4047	17.2497	1.5311	15.7391
VMRC-RCZ	GDSC2; CTRP2; CCLE	8.0924	18.0663	1.6431	14.2055
SNU-1272	CTRP2	8.2098	13.3259	4.0112	5.1495
TUHR14TKB	CTRP2	8.3554	13.4751	4.0329	4.8879
KMRC-20	GDSC2; CTRP2	8.6849	17.6066	2.2885	11.0122
KMRC-2	CTRP2; CCLE	10.1829	19.1744	2.5241	8.2056
RCC10RGB	GDSC1; GDSC2; CTRP2	12.6303	26.5204	0.6355	11.3662

Cancer Drug Sensitivity Data Curated from 60 Cell Line(s) in Large Intestine Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
DiFi	GDSC2	-1.9293	2.7432	-2.7978	33.429
CCK-81	GDSC2; CTRP2; CCLE	0.3928	5.2905	0.065	38.5626
NCI-H508	GDSC2; CTRP2	1.1583	7.4974	0.2549	35.2291
SW48	GDSC2; CTRP2; CCLE	1.3484	10.9907	-0.9438	37.2447
SW1116	GDSC2; CTRP2	1.434	7.6785	0.4881	33.6474
SNU-175	GDSC2	1.5263	7.6164	-1.8805	16.1395
HT115	GDSC2; CTRP2	1.667	6.1167	1.2472	30.5629
LoVo	GDSC2; CTRP2	1.796	5.6631	1.5063	29.2824
CaR-1	GDSC2	1.9412	4.9666	-0.2643	5.6419
SW403	CCLE	2.4471	6.8511	0.5962	14.4015
GP2d	CTRP2	2.5152	10.601	0.4212	30.4068
SW626	GDSC2	2.5517	5.7892	-0.2582	4.4187
SW837	GDSC2	2.8724	6.7327	-0.497	5.198
HT-55	GDSC2; CTRP2	2.8997	10.1682	1.0053	27.5503
GP5d	GDSC2	2.9086	7.6711	-0.9107	7.4528
COLO 320HSR	GDSC1; GDSC2	3.008	4.7066	0.4359	0.5573
SW1463	GDSC2	3.7086	15.4272	-4.0997	20.4602
COLO 678	GDSC2; CTRP2; CCLE	3.8803	10.2757	1.9352	21.7263
HCT 15	GDSC2; CTRP2; CCLE	4.0231	7.9374	3.1385	16.7667
SNU-407	GDSC2; CTRP2	4.0291	7.9956	3.1197	16.8238
CW-2	GDSC1; GDSC2; CTRP2	4.0344	7.4795	3.3422	15.9463
HCC2998	GDSC1; GDSC2	4.0928	6.497	0.2097	0.6315
SNU-61	GDSC2; CTRP2	4.161	9.5494	2.5512	18.6974
T84	GDSC2; CTRP2; CCLE	4.2205	9.1434	2.7988	17.5844
LS180	GDSC2; CTRP2	4.3615	10.1253	2.4747	18.495
NCI-H747	GDSC1; GDSC2; CTRP2; CCLE	4.486	15.6545	-0.1141	26.7404
SNU-283	GDSC2	4.5003	11.8806	-0.0195	16.7675
SNU-C2B	GDSC2; CCLE	4.6132	10.3938	0.5459	9.3915
SNU-81	GDSC2	4.8248	8.7978	1.7123	6.5287
COLO 320	CTRP2; CCLE	4.9837	10.4458	2.9074	15.3264
SNU-1033	CTRP2	5.0681	13.9245	1.2639	21.2482
NCI-H716	GDSC1; GDSC2; CTRP2	5.2063	7.9727	4.3161	9.0623
SNU-C4	CTRP2	5.2465	12.6382	2.061	18.0246
SK-CO-1	GDSC2; CTRP2; CCLE	5.4514	12.4581	2.3309	16.5628
MDST8	GDSC1; GDSC2; CTRP2	5.5771	8.6989	4.3101	8.2445
COLO201	CTRP2; CCLE	5.6358	9.807	3.8126	10.1952
SW620	GDSC2; CTRP2; CCLE	5.7247	9.4294	4.0787	8.8993
CL-11	GDSC1; GDSC2; CTRP2	5.8342	8.9963	4.3898	7.3713
OUMS-23	CTRP2	5.8499	9.8645	3.9699	9.0989
SW480	CCLE	6.0966	9.7037	1.7421	1.9887
DLD-1	CTRP2	6.1093	8.1903	5.025	4.161
SNU-C5	GDSC2; CTRP2	6.2765	10.5671	3.9735	8.2618
SNU-C2A	CTRP2; CCLE	6.3201	11.1761	3.7045	9.3013
SW1417	GDSC2; CTRP2; CCLE	6.3786	10.0098	4.3329	6.5735
SW948	GDSC2; CTRP2	6.525	8.7089	5.0883	3.1807
HT-29	GDSC2; CTRP2; CCLE	6.603	8.001	5.4832	1.4733
C2BBe1	GDSC1; GDSC2; CTRP2; CCLE	6.6658	14.7882	2.179	14.7311
SNU-C1	GDSC1; GDSC2; CTRP2	6.7738	11.814	3.7426	8.3397
LS123	GDSC1; GDSC2; CTRP2; CCLE	6.8607	12.8143	3.3134	9.9448
SNU-503	CTRP2	7.1834	17.1338	1.4179	16.5155
RKO	GDSC1; GDSC2; CTRP2; CCLE	7.3679	10.2619	4.91	2.7375
HCT 8	CTRP2	7.3983	12.7712	3.7317	7.3781
LS1034	GDSC1; GDSC2; CTRP2	7.7859	9.173	5.5871	0.2585
LS411N	GDSC1; GDSC2; CTRP2; CCLE	7.9859	9.3662	5.5948	0.1861
RCM-1 [Human ESC]	GDSC2; CTRP2	8.6072	20.3841	0.882	15.9043
HCT 116	GDSC2; CTRP2; CCLE	9.2608	20.5256	1.2775	13.6519
HCC-56	CTRP2; CCLE	9.262	19.2415	1.8966	11.5732
COLO205	GDSC2; CTRP2; CCLE	9.9883	20.211	1.9165	10.5289
LS513	GDSC1; CTRP2; CCLE	10.5803	24.2716	0.3776	14.5917
KM12	GDSC1; GDSC2; CTRP2	12.5419	25.4981	1.0509	10.2587

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Leukemia Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
MO-T	GDSC1; GDSC2	3.7794	5.5958	0.4128	0.2826

Cancer Drug Sensitivity Data Curated from 26 Cell Line(s) in Liver Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
JHH-5	CTRP2; CCLE	2.3647	9.6516	0.6851	30.097
Huh-7	GDSC2	2.7837	8.7263	-1.4966	10.9621
JHH-7	GDSC2; CCLE	2.9993	5.0999	1.9495	5.541
Hep-G2/C3A	GDSC2; CCLE	3.2423	4.7785	2.3037	3.125
SNU-878	CTRP2	3.5488	6.9665	3.0232	18.5206
HLE	GDSC2; CCLE	3.5548	7.1713	1.3567	7.4043
SNU-182	CTRP2; CCLE	4.4474	8.4987	3.3219	14.9435
HuH-6	CTRP2	4.7432	9.464	3.1579	14.878
JHH-4	GDSC2; CTRP2; CCLE	5.0925	10.9804	2.7442	15.7317
Li-7	CTRP2	5.3046	11.3783	2.7383	15.2884
JHH-1	GDSC2; CTRP2	5.7432	12.4107	2.6069	14.8828
SNU-761	CTRP2	6.1295	13.3689	2.4528	14.7098
SK-HEP-1	GDSC2; CTRP2; CCLE	6.6734	11.9448	3.6006	9.0967
SNU-423	GDSC2; CTRP2; CCLE	7.1027	10.3178	4.7123	3.8556
SNU-475	CTRP2; CCLE	7.1674	10.4099	4.7117	3.7688
PLC/PRF/5	CTRP2; CCLE	7.3216	11.9331	4.0845	6.0691
JHH-2	GDSC2; CTRP2; CCLE	7.3783	12.7838	3.7113	7.4911
JHH-6	GDSC2; CTRP2; CCLE	7.3905	8.2062	5.7821	0.065
Hep 3B2.1-7	GDSC2; CTRP2; CCLE	7.4169	14.9034	2.7002	11.435
HuH-1	GDSC2; CTRP2; CCLE	7.4848	13.9756	3.2057	9.3477
SNU-398	GDSC2; CTRP2; CCLE	7.5575	9.3841	5.4034	0.8316
HLF	CTRP2; CCLE	7.8571	11.7125	4.5408	3.5585
SNU-886	CTRP2	7.9095	10.2753	5.2068	1.1683
Hep-G2	CTRP2; CCLE	8.2889	21.796	-0.048	19.1878
SNU-387	GDSC2; CTRP2; CCLE	8.3556	10.1126	5.4682	0.288
SNU-449	GDSC2; CTRP2; CCLE	8.5462	15.7036	3.107	8.1708

Cancer Drug Sensitivity Data Curated from 226 Cell Line(s) in Lung Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HCC827	GDSC2; CTRP2; CCLE	-4.7784	1.3171	-4.8884	68.7821
PC-14	GDSC2; CTRP2; CCLE	-3.8619	4.1035	-4.3053	62.2333
HCC4006	CTRP2; CCLE	-3.2314	0.4198	-3.2439	61.4926
PaCa-3	GDSC2	-2.276	6.5096	-4.8032	40.6243
NCI-H3255	GDSC2; CCLE	-1.9369	2.497	-2.2148	44.5532
HCC2935	CTRP2; CCLE	-1.3206	5.0341	-1.7416	49.1964
NCI-H1648	GDSC1; GDSC2; CCLE	-0.7919	6.6298	-2.4852	37.2397
RERF-LC-Sq1	GDSC2	0.0819	8.4094	-3.4951	27.9034
NCI-H322	CTRP2; CCLE	0.0997	5.9394	-0.4148	40.8259
COR-L105	GDSC2; CTRP2; CCLE	0.2109	5.0215	-0.0746	39.6268
NCI-H1666	GDSC1; GDSC2; CTRP2; CCLE	0.2897	7.6858	-0.75	40.6783
NCI-H1623	GDSC2; CTRP2	0.6487	4.383	0.5122	36.3714
NCI-H358	GDSC2; CTRP2; CCLE	0.8443	5.8627	0.418	35.9239
NCI-H322M	GDSC1; GDSC2	1.0922	9.6184	-3.2326	23.7194
DMS 454	CTRP2	1.1746	3.4287	-2.6788	0.6823
LC-1/sq	GDSC2	1.2047	10.5738	-3.6174	24.8759
NCI-H209	GDSC1; GDSC2	1.2915	3.5188	-0.0255	5.6928
NCI-H2795	GDSC2	1.3816	5.8387	-1.1091	12.1614
NCI-H1781	GDSC2	1.6269	6.9605	-1.4753	13.6335
NCI-H513	GDSC2	1.6998	8.3236	-2.0962	16.7937
NCI-H2818	GDSC2	1.8476	5.325	-0.5033	7.3013
Calu-3	GDSC2; CTRP2; CCLE	1.8698	5.9745	1.5074	29.0395
NCI-H2722	GDSC2	1.9038	6.451	-1.0139	10.2431
UMC-11	GDSC2	1.9295	12.9753	-4.2317	25.0502
NCI-H2066	GDSC2	1.9464	6.3647	-0.9403	9.7036
EMC-BAC-2	GDSC2	2.0978	7.6591	-1.4648	12.3706
NCI-H2170	GDSC2; CTRP2; CCLE	2.1624	7.6409	1.2853	28.8495
Ms-1	GDSC1; GDSC2	2.174	4.2522	0.2168	2.4095
NCI-H1688	GDSC2	2.1786	8.6381	-1.8868	14.4652
NCI-H2369	GDSC2	2.189	6.578	-0.871	8.7282
NCI-H720	GDSC1; GDSC2	2.1978	3.3979	0.5917	0.5798
NCI-H1304	GDSC1	2.2631	3.808	0.4566	1.3489
COR-L279	GDSC2	2.2863	4.8012	0.0343	3.232
NCI-H596	GDSC2	2.3157	4.2366	0.302	1.759
NCI-H847	GDSC1; GDSC2	2.421	5.2246	-0.0784	3.6342
NCI-H1568	GDSC2; CTRP2; CCLE	2.4223	7.793	1.5066	27.3117
NCI-H2347	GDSC2	2.4304	4.7346	0.147	2.3953
EPLC-272H	GDSC2; CTRP2	2.4593	8.8227	1.1346	28.4276
EMC-BAC-1	GDSC2	2.5304	8.9784	-0.1903	23.3857
NCI-H1573	GDSC2; CTRP2; CCLE	2.5432	10.3161	0.5769	29.8802
NCI-H835	GDSC2	2.5799	5.4665	-0.0944	3.4608
NCI-H2141	GDSC1; GDSC2	2.5859	8.4964	-1.5229	11.5436
CPC-N	GDSC1; GDSC2	2.5915	5.0526	0.0959	2.4311
NCI-H187	GDSC1	2.6161	4.1778	0.4717	0.8704
Lu-99A	GDSC2	2.632	6.5314	-0.5527	5.9497
NCI-H1975	GDSC1; GDSC2; CTRP2; CCLE	2.6446	5.9162	2.3683	23.6087
NCI-H1963	GDSC1; GDSC2	2.6453	4.7189	0.2667	1.5266
NCI-H1734	GDSC2; CTRP2	2.6645	5.7922	2.4215	23.3588
COR-L311	GDSC2	2.6833	4.7987	0.2523	1.5501
EKVX	GDSC1; GDSC2; CTRP2	2.7216	16.6828	-2.2464	35.5981
Lu-165	GDSC1; GDSC2	2.7474	4.1012	0.5551	0.3525
NCI-H82	GDSC1; GDSC2	2.767	9.6383	-1.9499	13.3946
NCI-H524	GDSC1; GDSC2	2.768	5.6007	-0.0476	2.9244
LK-2	GDSC2	2.8053	4.7496	0.3309	1.0853
NCI-H64	GDSC1; GDSC2	2.8063	3.9969	0.6148	0.1906
NCI-H1876	GDSC1; GDSC2	2.904	7.3979	-0.7855	6.7582
Calu-6	GDSC1; GDSC2; CTRP2; CCLE	2.9954	4.4863	2.9804	20.3629
NCI-H1993	GDSC2	3.0065	4.8768	0.3706	0.7728
NCI-H2373	GDSC2	3.0339	6.2748	-0.1973	3.3205
NCI-H2591	GDSC2	3.0442	8.0075	-0.9819	7.5899
CAL-12T	GDSC2; CTRP2; CCLE	3.0901	15.9293	-1.5339	33.3994
NCI-H2595	GDSC2	3.1637	5.192	0.3169	0.8488
RERF-LC-KJ	GDSC2	3.1642	13.284	-3.445	19.2356
SBC-3	GDSC2	3.1861	5.6385	0.1503	1.4777
SK-MES-1	GDSC2; CTRP2; CCLE	3.1874	9.6128	1.5461	24.9556
LC-2/ad	GDSC1; GDSC2	3.2289	9.6751	0.0675	19.2987
NCI-H2461	GDSC2	3.2367	11.5336	-2.5393	15.2132
NCI-H1869	GDSC1; GDSC2; CTRP2; CCLE	3.2468	12.4038	0.3123	28.6556
NCI-H128	GDSC1	3.2527	4.7203	0.5257	0.2815
Lu-135	GDSC2	3.3804	5.2679	0.3781	0.5234
NCI-H1435	GDSC2; CTRP2	3.4284	8.613	2.2326	21.8288
Sq-1	CTRP2; CCLE	3.5357	7.2114	2.9182	18.9527
DV-90	CTRP2; CCLE	3.5816	8.5749	2.4071	20.7596
NCI-H1651	GDSC2; CCLE	3.6011	6.5583	1.6936	5.562
NCI-H1048	GDSC2; CCLE	3.6035	5.5226	2.1993	2.9651
NCI-H2731	GDSC2	3.6327	5.8411	0.2674	0.7091
NCI-H3122	GDSC2	3.6563	5.7351	0.3161	0.5563
Lu-139	GDSC1	3.6703	5.4321	0.43	0.3524
LCLC-97TM1	GDSC2; CTRP2	3.7096	7.5529	2.9698	18.2694
IST-SL2	GDSC1; GDSC2	3.7508	6.7827	1.9346	6.1733
NCI-H2227	GDSC1; GDSC2	3.7612	7.594	1.5401	9.684
NCI-H1755	GDSC2; CTRP2	3.7793	8.1678	2.787	18.7796
COLO 677	CCLE	3.9614	6.2432	2.0925	2.9768
Lu-134-A	GDSC1; GDSC2	3.9967	6.067	2.4629	3.6316
NCI-H1355	GDSC1; GDSC2; CTRP2; CCLE	4.0308	10.0325	2.1969	20.3747
NCI-H2171	GDSC1; GDSC2	4.0459	6.1218	2.4696	3.4937
NCI-H1437	GDSC2	4.125	7.4206	1.8972	6.9254
COR-L23	GDSC2; CCLE	4.1597	8.0364	1.3705	6.1489
NCI-H1581	GDSC1; GDSC2; CTRP2; CCLE	4.1678	7.448	3.4953	14.9909
NCI-H345	GDSC1; GDSC2	4.2351	5.2639	2.9652	0.6035
GLC-82	CCLE	4.2875	9.3599	0.8187	8.9021
A-427	GDSC2	4.2923	6.9779	2.2257	4.5732
NCI-H661	GDSC2; CTRP2; CCLE	4.3651	10.6205	2.241	19.3788
NCI-H2810	GDSC2	4.3652	10.0704	0.7728	12.9757
NCI-H2030	GDSC2; CTRP2; CCLE	4.3703	11.124	2.003	20.2553
COR-L321	GDSC2	4.3857	8.1707	1.7166	7.4276
NCI-H2804	GDSC2	4.4033	8.571	1.5349	8.4748
NCI-H2286	CTRP2; CCLE	4.4487	9.036	3.0745	15.9258
NCI-H1944	GDSC2; CTRP2; CCLE	4.4589	15.1401	0.1159	26.1742
SW900	CCLE	4.4609	6.8193	2.1265	2.104
SK-LU-1	GDSC2; CTRP2; CCLE	4.4661	8.2155	3.4697	14.3074
NCI-H1563	GDSC2; CTRP2; CCLE	4.5118	10.8657	2.2618	18.9463
HARA [Human squamous cell lung carcinoma]	GDSC2; CTRP2; CCLE	4.5735	10.4529	2.5199	17.8087
NCI-H2228	GDSC2; CTRP2; CCLE	4.6122	9.3416	3.0901	15.4637
NCI-H2405	GDSC2; CTRP2	4.6812	8.6045	3.5052	13.627
NCI-H2110	GDSC2; CTRP2	4.7166	10.9425	2.4166	17.871
NCI-H1838	GDSC1; GDSC2; CTRP2	4.7278	10.8567	2.4689	17.6426
NCI-H2803	GDSC2	4.7355	8.2304	1.922	5.4855
IST-SL1	GDSC1; GDSC2	4.7375	7.6456	2.1949	3.7815
NCI-H1373	CTRP2; CCLE	4.8198	7.8439	3.9944	11.3136
LB647-SCLC	GDSC1; GDSC2	4.9197	8.2415	2.0318	4.3631
DMS 53	GDSC2; CTRP2	4.9312	11.0999	2.538	16.9058
HCC1171	CTRP2	4.9322	10.6426	2.7633	16.0176
NCI-H1693	GDSC2; CTRP2; CCLE	5.0074	12.916	1.7102	19.8346
Lu-65	GDSC1; GDSC2; CTRP2	5.0367	9.5646	3.3873	13.2636
NCI-H290	GDSC2	5.0416	13.5427	-0.4358	17.3851
HCC2108	CTRP2	5.1005	9.2107	3.6192	12.1682
SBC-1	GDSC1; GDSC2	5.1019	6.7829	2.7552	0.6904
NCI-H2135	GDSC1; GDSC2	5.1405	6.9068	2.7239	0.7713
NCI-H1184	CTRP2; CCLE	5.2602	9.6791	3.5383	12.1407
LUDLU-1	CTRP2; CCLE	5.2919	11.6992	2.5678	15.9883
NCI-H2009	GDSC2; CTRP2; CCLE	5.3394	11.7752	2.5722	15.8682
HCC15	GDSC2; CTRP2; CCLE	5.3518	9.6374	3.6425	11.509
NCI-H650	GDSC2; CTRP2; CCLE	5.365	8.794	4.0692	9.7129
COR-L303	GDSC2	5.4196	7.0356	2.7912	0.4142
NCI-H146	GDSC2; CTRP2	5.4307	9.683	3.6913	11.1353
NCI-H250	GDSC2	5.4554	7.6114	2.5876	1.0602
NCI-H1703	GDSC2; CTRP2; CCLE	5.4642	9.3458	3.8884	10.2449
HCC95	CTRP2	5.4729	13.2962	1.9319	18.0144
HOP-92	GDSC2; CTRP2	5.4889	13.5387	1.8248	18.3711
Lu-99	CTRP2; CCLE	5.4986	10.9	3.148	13.2251
NCI-H740	GDSC2	5.5303	9.1504	1.9773	3.8339
HCC33	GDSC1; GDSC2	5.5636	7.0399	2.8444	0.2275
NCI-H2085	GDSC2; CTRP2; CCLE	5.571	11.8252	2.7506	14.6724
NCI-H292	GDSC2; CTRP2	5.5921	18.0019	-0.3153	24.8632
NCI-H69	GDSC1; GDSC2; CTRP2	5.5949	9.6241	3.8674	10.0528
COR-L32	GDSC2	5.6099	7.6621	2.6351	0.6294
NCI-H510A	GDSC1; GDSC2	5.7071	7.334	2.7941	0.2807
NCI-H748	GDSC1; GDSC2	5.712	7.6055	2.6981	0.5058
EBC-1	GDSC2; CTRP2; CCLE	5.7535	9.1639	4.236	8.1813
ABC-1	GDSC2	5.7603	8.2668	2.4659	1.276
NCI-H1836	GDSC1; GDSC2	5.7652	7.3607	2.8062	0.2391
RERF-LC-MS	GDSC2; CTRP2; CCLE	5.7838	9.3997	4.145	8.5002
NCI-H2869	GDSC2	5.8659	8.2841	2.5058	1.0436
NCI-H1770	GDSC1; GDSC2	5.8719	7.153	2.9141	0.0708
NCI-H1436	GDSC1; GDSC2	5.9313	7.4879	2.822	0.1704
KNS-62	GDSC2; CTRP2; CCLE	5.9465	11.2224	3.3733	11.3857
NCI-H446	GDSC1; GDSC2; CTRP2	5.9536	10.7323	3.6244	10.3335
Hs 229.T	CCLE	6.018	8.4551	2.1953	0.6071
HCC44	GDSC2; CTRP2; CCLE	6.0295	9.9003	4.104	8.1824
NCI-H841	GDSC2; CTRP2	6.03	13.0895	2.5098	14.6847
COR-L47	CTRP2	6.0342	9.1772	4.4695	6.6392
VMRC-LCD	GDSC2; CTRP2; CCLE	6.0374	9.3948	4.3633	7.0791
NCI-H1155	GDSC1; GDSC2; CTRP2; CCLE	6.055	11.2332	3.4588	10.8212
COLO 699	CTRP2; CCLE	6.0647	9.7832	4.1919	7.7458
NCI-H1650	GDSC1; GDSC2; CTRP2; CCLE	6.0795	16.0609	1.0654	19.7774
RERF-LC-A1	CTRP2; CCLE	6.1858	11.2574	3.5547	10.1736
DMS 79	GDSC1; GDSC2	6.2269	15.7263	-0.658	15.3609
NCI-H2122	GDSC2; CTRP2; CCLE	6.2588	20.161	-0.8361	24.8713
DMS 114	GDSC1; GDSC2; CTRP2; CCLE	6.2652	9.239	4.6272	5.5443
IA-LM	GDSC2; CTRP2; CCLE	6.288	8.7264	4.9006	4.358
Calu-1	CTRP2; CCLE	6.3764	11.933	3.372	10.5696
LOU-NH91	GDSC2; CTRP2; CCLE	6.422	16.8808	0.9376	19.5209
NCI-H1339	CTRP2; CCLE	6.4235	8.7248	5.0055	3.6874
RERF-LC-Ad1	CTRP2	6.4349	8.7961	4.9788	3.7795
NCI-H1915	GDSC2; CTRP2; CCLE	6.4392	12.6549	3.0621	11.7128
NCI-H1793	GDSC2; CTRP2; CCLE	6.4474	16.8918	0.9528	19.4233
NCI-H1341	GDSC2; CTRP2; CCLE	6.4644	11.3473	3.7344	8.9148
NCI-H1694	GDSC1; GDSC2; CTRP2; CCLE	6.4687	9.6841	4.5649	5.4461
NCI-H2291	GDSC2; CTRP2	6.482	11.9936	3.4262	10.1538
LK2	CTRP2	6.5144	7.9547	5.4468	1.7364
COR-L88	GDSC1; GDSC2; CTRP2	6.5346	11.8806	3.5241	9.6569
NCI-H1792	GDSC2; CTRP2; CCLE	6.5862	12.4542	3.2791	10.5665
A-549	GDSC2; CTRP2; CCLE	6.6186	13.3098	2.8785	12.1187
NCI-H647	GDSC2; CTRP2; CCLE	6.6193	10.8141	4.1201	7.0412
NCI-H196	GDSC2; CTRP2	6.6475	10.0929	4.4982	5.4234
SW1271	GDSC2; CTRP2; CCLE	6.6693	9.6829	4.716	4.487
NCI-H211	GDSC1; GDSC2; CTRP2; CCLE	6.6879	9.1255	5.0016	3.286
HOP-62	GDSC1; GDSC2; CTRP2	6.7464	16.6935	1.293	17.734
NCI-H526	GDSC1; GDSC2; CTRP2	6.8523	10.2995	4.5468	4.8959
LXF 289	GDSC1; GDSC2; CTRP2	6.8809	15.5244	1.9822	15.0645
HCC2279	CTRP2	6.9094	12.4596	3.526	8.9976
NCI-H1385	CTRP2	6.9114	15.6522	1.9425	15.1541
LC-1/sq-SF	CTRP2; CCLE	6.9391	16.6575	1.4638	16.7975
NCI-H226	GDSC1; GDSC2; CTRP2; CCLE	6.9432	8.9523	5.2538	1.9364
SBC-5	GDSC2; CTRP2; CCLE	6.9605	8.2383	5.584	0.7287
HCC1588	CTRP2	6.9898	13.3146	3.164	10.3258
SW1573	GDSC2; CTRP2; CCLE	6.9913	13.0998	3.2714	9.8916
DMS 273	GDSC2; CTRP2	7.0004	10.867	4.3759	5.3678
HCC1833	CTRP2	7.0065	10.3173	4.6469	4.2561
NCI-H2106	CTRP2	7.0091	10.8733	4.3791	5.3415
NCI-H23	GDSC1; GDSC2; CTRP2; CCLE	7.0229	10.1133	4.7563	3.7915
NCI-H520	GDSC2; CTRP2; CCLE	7.0363	9.5059	5.054	2.5924
NCI-H838	GDSC2; CTRP2	7.0947	10.5565	4.5923	4.3491
NCI-H1299	GDSC2; CTRP2; CCLE	7.149	12.9469	3.4649	8.8491
COLO 668	GDSC1; GDSC2; CTRP2	7.151	9.0573	5.3296	1.4236
HCC366	GDSC2; CTRP2	7.1571	13.7254	3.0872	10.3505
HCC78	GDSC2; CTRP2; CCLE	7.1928	10.9938	4.449	4.7855
NCI-H522	GDSC2; CTRP2; CCLE	7.2352	12.5372	3.729	7.6414
NCI-H1395	CTRP2	7.2744	11.8243	4.1043	6.0593
NCI-H441	GDSC2; CTRP2; CCLE	7.2973	13.8845	3.1132	10.0158
RERF-LC-Ad2	CTRP2	7.3295	12.1981	3.9616	6.5541
COR-L95	GDSC1; CTRP2	7.377	9.1116	5.4273	0.8924
HCC1438	CTRP2	7.3826	11.0158	4.5659	4.056
NCI-H1105	GDSC2; CTRP2	7.3915	10.9856	4.586	3.9648
NCI-H2087	GDSC2; CTRP2; CCLE	7.395	14.4363	2.914	10.6408
ChaGo-K-1	GDSC2; CTRP2	7.3968	10.8166	4.6693	3.6313
NCI-H2444	GDSC2; CTRP2; CCLE	7.4249	14.9113	2.7023	11.4139
NCI-H727	GDSC2; CTRP2; CCLE	7.5381	13.2162	3.6142	7.6379
NCI-H2342	GDSC2; CTRP2	7.5828	11.6268	4.4076	4.4143
LCLC-103H	GDSC2; CTRP2; CCLE	7.604	11.3184	4.5662	3.7686
SHP-77	GDSC1; GDSC2; CTRP2; CCLE	7.6326	9.2846	5.4791	0.5719
NCI-H2172	GDSC2; CTRP2; CCLE	7.6582	12.0312	4.2655	4.8728
NCI-H2126	CTRP2	7.6985	10.5418	4.9787	2.1182
NCI-H2023	GDSC2; CTRP2; CCLE	7.711	12.5945	4.0325	5.7209
NCI-H2196	GDSC1; GDSC2; CTRP2	7.7268	9.4231	5.4668	0.5512
NCI-H810	GDSC2; CTRP2; CCLE	7.7658	9.053	5.623	0.2014
HCC1195	CTRP2	7.8784	13.2202	3.8458	6.2275
NCI-H1092	GDSC1; GDSC2; CTRP2; CCLE	8.0526	9.6961	5.5008	0.3289
NCI-H2029	GDSC2; CTRP2	8.0645	9.3861	5.6171	0.1371
T3M-10	CTRP2; CCLE	8.0687	10.3798	5.2413	0.9546
NCI-H2081	GDSC1; GDSC2; CTRP2	8.6286	10.341	5.4902	0.1851
NCI-H460	GDSC2; CTRP2; CCLE	11.8414	24.5194	1.0748	10.9637
MOR/CPR	CTRP2; CCLE	12.0472	24.6279	1.1511	10.502
BEN	GDSC2; CTRP2	12.8515	34.3769	-2.9289	19.7419
Hs 888.Lu	CTRP2	5.5431	9.2557	4.0039	9.5941

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Lymphoma Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
CBTCi002-A	GDSC1; GDSC2	3.1559	5.3477	0.2527	1.0914

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Clivus Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
U-CH1	CTRP2	3.0169	9.8098	1.2847	26.3149

Cancer Drug Sensitivity Data Curated from 31 Cell Line(s) in Soft Tissue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
Yamato-SS	CTRP2	5.1974	8.4172	4.0948	9.9901
Aska-SS	CTRP2	6.4315	9.2394	4.7569	4.7091
TE 617.T	CTRP2; CCLE	1.3357	3.676	1.3104	31.4544
Hs 633.T	GDSC2	2.3791	4.9122	0.0386	3.0556
SW684	GDSC1; GDSC2	2.3913	3.792	0.5232	0.6834
EW-8	GDSC1; GDSC2	2.462	4.6067	0.2199	1.9769
SW872	GDSC1; GDSC2	2.5525	4.1304	0.462	0.7852
VA-ES-BJ	GDSC1; GDSC2	2.5682	4.7615	0.2094	1.8915
MFH-ino	GDSC1; GDSC2	3.5424	5.7782	0.2537	0.8067
STS-0421	GDSC2	3.797	5.8699	2.4189	4.4753
Rh41	GDSC2; CTRP2	4.2091	7.781	3.3982	15.2582
BT-16	CTRP2	4.3989	8.6701	3.1948	15.5714
MES-SA	GDSC2; CCLE	4.4863	6.6863	2.1985	1.7092
TE 441.T	GDSC1; GDSC2; CTRP2	4.5849	7.4472	3.9307	12.173
A-204	GDSC2; CTRP2; CCLE	4.7536	10.8855	2.4789	17.5439
Rh30	GDSC2; CCLE	4.807	8.2618	1.6789	3.6154
GCT	GDSC2; CTRP2; CCLE	4.8593	9.3162	3.3399	13.8682
SW982	GDSC2; CTRP2	5.5344	8.9093	4.1675	8.9315
SK-LMS-1	GDSC1; GDSC2; CTRP2; CCLE	5.742	9.2953	4.1606	8.5209
Rh18	CTRP2	5.902	10.5378	3.6779	10.2131
G-401	GDSC2; CTRP2; CCLE	6.3603	10.4158	4.1161	7.513
TTC-709	CTRP2	6.4304	9.9902	4.3832	6.2714
G-402	GDSC2; CTRP2; CCLE	6.4314	9.7027	4.5269	5.6694
HT-1080	GDSC2; CTRP2; CCLE	6.4896	10.1821	4.3339	6.374
Tm87-16	CTRP2	6.7653	9.7588	4.7483	4.204
KYM-1	GDSC2; CTRP2; CCLE	6.9139	9.787	4.8388	3.6147
BT-12	CTRP2	7.0311	10.451	4.5993	4.413
Hs 729.T	CTRP2; CCLE	7.4992	11.6	4.3654	4.6921
RD	GDSC2; CTRP2; CCLE	7.6636	11.7632	4.3955	4.3559
SK-UT-1	GDSC1; GDSC2; CTRP2	8.3748	11.346	4.9915	1.4794
RKN	GDSC2; CTRP2; CCLE	8.3881	13.2292	4.1665	4.3467

Cancer Drug Sensitivity Data Curated from 50 Cell Line(s) in Ovary Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
2004	CTRP2	5.8865	9.4795	4.1936	8.0885
SNU-119	CTRP2	2.2597	6.3565	1.8248	26.7169
IGROV-1	GDSC2; CTRP2; CCLE	2.541	9.0252	1.1352	28.181
Caov-4	GDSC2	2.5918	10.0076	-2.2559	15.3365
JHOS-4	GDSC2; CCLE	2.9375	8.7964	0.2581	16.8228
OVCAR-3	GDSC2; CCLE	3.0678	8.7427	0.1849	14.4775
COV504	CCLE	3.543	7.6099	1.1305	8.8351
JHOC-5	CTRP2	3.5994	10.3788	1.6101	23.6181
OC 316	CCLE	3.8015	6.3604	1.9318	4.0714
OC 315	CCLE	3.8153	5.7994	2.2074	2.6396
OVMANA	CCLE	4.0146	6.9243	1.8054	4.3405
COV434	CTRP2	4.085	9.581	2.4614	19.2347
ES-2	GDSC1; GDSC2; CCLE	4.1752	6.7455	1.9925	3.0506
ONCO-DG-1	CTRP2; CCLE	4.2506	12.8405	1.056	23.8365
SNU-8	CTRP2	4.3573	13.1911	0.9832	23.8141
OVTOKO	GDSC2; CTRP2; CCLE	4.4236	10.7401	2.239	19.2444
SNU-840	CTRP2	4.5052	14.1633	0.6403	24.536
FU-OV-1	GDSC2; CTRP2; CCLE	4.5855	10.1396	2.6825	17.1451
COV318	CCLE	4.6466	5.9808	2.5593	0.3354
SK-OV-3	GDSC2; CTRP2; CCLE	4.7772	9.4968	3.1746	14.7301
A2780	GDSC2; CTRP2; CCLE	4.8292	9.1077	3.4111	13.6506
OV7	CTRP2	4.9893	7.5782	4.2857	9.7175
OAW28	GDSC2; CTRP2	5.0304	10.576	2.8865	15.3043
RMG-I	GDSC2; CTRP2	5.3501	17.0692	-0.0568	24.6708
OVCAR-5	GDSC2; CTRP2	5.3532	13.6482	1.6521	19.2809
OVKATE	GDSC2	5.5258	18.5218	-4.3368	17.7622
Caov-3	GDSC2; CTRP2	5.5437	11.281	2.998	13.7385
HEY A8	CTRP2; CCLE	5.556	10.4365	3.4292	11.9517
EFO-27	GDSC2; CTRP2; CCLE	5.7194	13.9503	1.8175	17.9144
OC 314	GDSC2; CTRP2; CCLE	5.8558	11.5122	3.1518	12.4737
MCAS	CTRP2; CCLE	6.2238	14.7961	1.8171	16.901
OVK18	GDSC2; CTRP2	6.3899	9.4529	4.6188	5.3577
TOV-21G	GDSC2; CTRP2; CCLE	6.459	10.3165	4.2432	6.8059
TYK-nu	GDSC2; CTRP2; CCLE	6.7415	13.2009	3.0292	11.2973
DOV13	GDSC2; CTRP2; CCLE	6.7518	11.0044	4.1264	6.7916
OV56	GDSC2; CTRP2	6.7556	8.0604	5.5493	1.0439
OVSAHO	CTRP2; CCLE	6.7596	11.0895	4.0902	6.9282
Kuramochi	GDSC1; GDSC2; CTRP2; CCLE	6.8163	12.0283	3.6689	8.5705
OV-90	GDSC2; CTRP2; CCLE	6.863	8.8205	5.2648	1.9926
JHOS-2	GDSC2; CTRP2; CCLE	7.0707	11.9422	3.901	7.2009
COV362	CTRP2	7.2427	10.5255	4.7066	3.6871
JHOM-1	CTRP2	7.4378	11.1152	4.555	4.0258
COV644	CTRP2	7.7341	17.1866	1.8111	14.2021
EFO-21	GDSC2; CTRP2; CCLE	7.8294	11.0237	4.838	2.4881
OAW42	GDSC2; CTRP2	8.014	16.3642	2.4197	11.5403
TOV-112D	GDSC2; CTRP2; CCLE	8.1802	21.4395	0.0463	19.0984
ES2	CTRP2	8.6444	17.0435	2.5318	10.1834
OVISE	GDSC2; CTRP2	11.6292	28.8926	-1.1273	17.2432
OVCAR-8	GDSC2; CTRP2; CCLE	12.4527	26.9939	0.3067	12.4921
OVCAR-4	GDSC1; GDSC2; CTRP2; CCLE	13.2416	28.1797	0.2445	11.7942

Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Thigh Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SYO-1	CTRP2	6.2565	8.4769	5	3.9972
H-STS	CTRP2	6.5447	7.9688	5.4604	1.6404
P-STS	CTRP2	7.8185	9.221	5.5824	0.2562

Cancer Drug Sensitivity Data Curated from 9 Cell Line(s) in Pleura Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
MSTO-211H	GDSC1; GDSC2; CTRP2; CCLE	3.3871	7.6519	2.5888	20.6119
IST-Mes2	CCLE	3.4324	5.6764	2.0028	4.418
NCI-H2052	GDSC2; CTRP2; CCLE	4.0349	8.4462	2.9285	17.5539
NCI-H2452	GDSC2; CTRP2; CCLE	5.7773	9.7353	3.9719	9.2376
NCI-H28	GDSC2; CTRP2; CCLE	5.9049	11.4671	3.2159	12.1136
MPP 89	GDSC1; GDSC2; CTRP2; CCLE	7.4665	13.2249	3.5592	7.967
IST-Mes1	GDSC1; GDSC2; CTRP2; CCLE	7.4926	12.693	3.836	6.8169
ACC-MESO-1	CTRP2	8.2304	14.0599	3.6793	6.4021
JL-1	CTRP2	9.5229	35.5651	-5.9267	28.9305

Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Prostate Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
PC-3	GDSC2; CCLE	3.7299	7.5756	1.2883	7.3946
LNCaP clone FGC	GDSC1; GDSC2; CTRP2	5.2383	8.9989	3.8514	10.8989
22Rv1	GDSC2; CTRP2; CCLE	6.7127	10.2266	4.4808	5.3891
PaCa-3	CTRP2	7.019	9.1924	5.1895	2.0906
NCI-H660	GDSC2; CTRP2	7.2009	14.298	2.8373	11.2627
DU145	GDSC2; CTRP2; CCLE	7.686	14.7193	2.9873	9.8897
VCaP	GDSC1; GDSC2; CTRP2	8.3328	9.8289	5.5607	0.1547

Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Salivary Gland Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
YD-15	CTRP2	0.8314	5.8238	0.414	35.9824
A-253	GDSC1; GDSC2; CCLE	3.9294	11.7791	-0.6411	16.2667

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Small Intestine Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HuTu 80	GDSC1; GDSC2	2.8093	5.1451	1.9545	9.9172

Cancer Drug Sensitivity Data Curated from 46 Cell Line(s) in Stomach Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SK-GT-2	GDSC2	-1.0775	0.9601	-1.2565	21.7875
NCC-StC-K140	CTRP2	-0.5383	11.5636	-3.1452	46.3651
NUGC-4	GDSC2; CTRP2; CCLE	0.2369	6.4501	-0.4087	40.2499
SNU-216	CTRP2	1.8343	8.2214	0.7145	31.6695
NCI-N87	GDSC2; CTRP2; CCLE	1.881	3.5994	1.8734	27.7628
NUGC-3	GDSC2; CTRP2; CCLE	1.8885	11.4894	-0.6129	34.8642
AZ-521	CCLE	1.9208	5.368	0.8292	14.7391
TGBC11TKB	GDSC2	2.2701	7.6613	-1.3407	11.2585
MKN28	GDSC2	2.7081	7.6047	-1.0103	8.416
HSC-39	GDSC1; GDSC2	2.8185	4.239	0.5327	0.3783
RF-48	GDSC1; GDSC2	2.9487	5.8657	-0.065	2.7607
ECC10	GDSC2; CTRP2	3.1849	6.9297	2.6439	20.9858
SCH	GDSC1; GDSC2	3.3743	6.0443	2.0041	7.9073
SNU-16	GDSC1; GDSC2; CTRP2; CCLE	3.8142	6.6201	3.4321	16.2251
GCIY	GDSC1; GDSC2; CCLE	3.8289	14.581	-2.1151	22.1419
TMK-1	GDSC2	3.8398	8.1697	1.3149	11.1827
BGC-823	CCLE	3.8554	6.9418	1.6884	5.2382
KE-39	CTRP2; CCLE	3.8578	11.7431	1.2167	24.2868
GSS	CTRP2	3.8743	6.6833	3.4752	15.8898
KATO III	GDSC2; CTRP2	3.9382	8.0753	2.9914	17.5648
RERF-GC-1B	GDSC2; CCLE	3.9506	9.2638	0.6207	10.3277
HGC-27	GDSC2; CTRP2; CCLE	4.4241	10.4511	2.3787	18.7114
SNU-1	GDSC1; GDSC2; CTRP2; CCLE	4.8318	9.0443	3.4438	13.5114
SNU-601	CTRP2	4.841	11.467	2.2748	18.1265
Fu97	GDSC2; CTRP2; CCLE	5.2729	8.4183	4.166	9.5219
Hs 746.T	GDSC2; CTRP2; CCLE	6.101	9.8481	4.1895	7.6863
23132/87	GDSC2; CTRP2	6.1042	15.6885	1.2721	19.0409
MKN74	CTRP2; CCLE	6.1162	12.669	2.7917	13.4081
SNU-620	CTRP2	6.1742	8.5026	4.9218	4.4741
MKN1	GDSC2; CTRP2	6.2995	11.8652	3.3438	10.8278
SNU-5	GDSC1; GDSC2; CTRP2	6.3572	9.7309	4.4549	6.1008
GSU	CTRP2	6.4796	10.1054	4.3642	6.265
IM95	GDSC2; CTRP2; CCLE	6.9821	15.6094	2.0191	14.7476
LMSU	CTRP2	7.1553	10.5343	4.6442	4.0548
MKN45	GDSC2; CTRP2; CCLE	7.1793	8.3971	5.6256	0.4481
ECC12	GDSC1; GDSC2; CTRP2	7.2536	12.4372	3.7911	7.3608
HuG1-N	CTRP2	7.7309	11.2368	4.6828	3.1703
SNU-719	CTRP2	7.8728	13.419	3.7471	6.6238
MKN7	GDSC2; CTRP2; CCLE	7.9586	15.41	2.8451	10.019
SNU-668	CTRP2	7.9896	14.0211	3.5376	7.2834
AGS	GDSC2; CTRP2	8.0304	13.9669	3.591	7.017
OCUM-1	GDSC2; CTRP2; CCLE	8.192	9.8388	5.5038	0.2766
SH-10-TC	CTRP2; CCLE	9.2218	17.3949	2.7484	8.6019
SNG-M	GDSC2; CTRP2; CCLE	3.5231	6.8385	3.0414	18.5269
SNU-1077	CTRP2	6.0376	9.7529	4.1845	7.8293
SNU-685	CTRP2	7.2506	10.6048	4.6741	3.8053

Cancer Drug Sensitivity Data Curated from 18 Cell Line(s) in Thyroid Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HTC-C3	GDSC2	1.9267	5.2792	-0.4251	6.6464
WRO	GDSC2	2.1879	4.57	0.081	3.1373
IHH-4	GDSC2	2.3867	3.8024	0.517	0.7108
ASH-3	GDSC2	2.5974	4.2445	0.4372	0.844
K5	GDSC1; GDSC2	3.8929	5.4578	0.5002	0.122
8305C	GDSC2; CTRP2; CCLE	3.9612	7.6919	3.1776	16.7817
TT	GDSC2; CTRP2	4.214	12.4487	1.2129	23.4106
KMH-2	GDSC2	4.5685	7.1181	2.3347	3.4207
ML-1 [Human leukemia]	GDSC2; CTRP2	5.0926	8.6463	3.8847	11.0975
B-CPAP	GDSC2; CTRP2; CCLE	5.1493	10.4895	3.038	14.4291
SW579	CTRP2; CCLE	5.8502	9.1546	4.3247	7.6118
CAL-62	GDSC2; CTRP2	6.0454	9.726	4.2044	7.7306
CGTH-W-1	GDSC1; GDSC2; CTRP2	6.4564	10.7719	4.0146	7.7641
FTC-238	CTRP2	6.5246	9.6827	4.6083	5.1705
TT2609-C02	GDSC2; CTRP2; CCLE	6.6955	10.5545	4.3063	6.1397
FTC-133	GDSC2; CTRP2	6.9898	10.0776	4.7509	3.8601
8505C	GDSC2; CTRP2; CCLE	8.0158	14.414	3.3668	7.914
BHT-101	GDSC2; CTRP2	8.3523	16.1385	2.7672	9.7291

Cancer Drug Sensitivity Data Curated from 56 Cell Line(s) in Upper Aerodigestive Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
YD-10B	CTRP2	-3.8032	5.0427	-4.4465	61.2681
DOK	GDSC2	-2.3078	4.3043	-3.8443	38.7406
BB30-HNC	GDSC1; GDSC2	-1.6003	3.3732	-2.0639	48.1166
SNU-1076	CTRP2	-1.3405	5.222	-1.8062	49.3192
Ca9-22	GDSC2	-0.3228	5.0654	-2.2184	23.8646
NCI-H3118	GDSC2	-0.1286	7.6103	-3.2871	27.849
SAT [Human HNSCC]	GDSC2	0.2286	4.449	-1.4031	17.4566
JHU-029	GDSC2	0.2788	4.5827	-0.4122	33.7435
BHY	GDSC2; CTRP2	0.4054	5.3263	0.0706	38.4992
UPCI-SCC-090	GDSC2	0.661	6.6761	-2.1253	19.9915
BICR 56	CTRP2	0.6691	9.9894	-1.226	40.0483
JHU-022	GDSC2	0.6827	9.8421	-3.6882	26.6761
PCI-15A	GDSC2	0.7349	6.2963	-0.6373	32.4273
CAL-27	GDSC2; CTRP2; CCLE	0.7853	6.4291	0.1955	36.7339
HO-1-u-1	GDSC2	0.9419	7.1215	-2.1093	19.035
SNU-1214	CTRP2	0.9613	6.1908	0.4564	35.3924
JHU-011	GDSC2	1.396	9.4819	-1.4805	32.5731
PE/CA-PJ34 (clone C12)	CTRP2	1.3978	6.2542	0.9146	32.5189
SAS	GDSC2	1.4965	5.1323	-0.6684	9.175
HO-1-N-1	GDSC2	1.5808	4.7411	-0.4114	7.3736
SCC-25	GDSC2; CTRP2	1.8246	5.6298	1.5455	29.0573
PCI-06A	GDSC2	1.8738	9.4866	-1.0372	29.2644
HSC-2	GDSC2; CTRP2; CCLE	2	7.9271	1.0041	30.2603
OSC-20	GDSC2	2.0133	5.6124	-0.5261	7.0635
BICR 78	GDSC2	2.0395	9.3	-2.3187	17.0115
KON	GDSC2	2.2323	12.1129	-2.0116	31.2058
SCC-15	GDSC1; GDSC2	2.3299	7.4699	-1.2048	10.3477
PCI-30	GDSC2	2.3951	9.2686	-2.0371	14.7131
CAL-33	GDSC2; CTRP2	2.5232	8.7153	1.2461	27.8751
PCI-04B	GDSC2	2.599	9.896	-0.5855	24.9247
KOSC-2	GDSC2	2.6166	9.2245	-0.2359	23.307
SKN-3	GDSC2	2.6792	10.2569	-2.3146	15.4162
BICR 10	GDSC2	2.8659	12.3856	-3.2225	19.0297
HSC-3	GDSC2; CTRP2	3.0689	12.4233	0.1301	29.638
SNU-1041	CTRP2	3.551	10.2517	1.621	23.7085
Hs 840.T	CCLE	3.6027	6.6816	1.6342	6.0276
SNU-1066	CTRP2	3.7024	10.9171	1.4593	23.8697
HSC-4	GDSC2; CTRP2	3.8251	14.6584	-0.2278	28.6191
OSC-19	GDSC2	3.8381	8.2602	1.2687	11.4645
SCC-9	GDSC2; CTRP2; CCLE	3.899	10.8221	1.6956	22.5394
BB49-HNC	GDSC1; GDSC2	3.8993	6.256	0.2212	0.6979
PE/CA-PJ49	CTRP2	3.9083	10.7623	1.733	22.383
LB771-HNC	GDSC1; GDSC2	4.2698	15.6328	-3.8031	18.2495
BICR 22	GDSC2; CTRP2	4.3901	12.2854	1.4569	22.1577
SNU-899	CTRP2	4.4551	8.9663	3.1134	15.7554
PE/CA-PJ15	GDSC2; CTRP2	4.4709	12.3259	1.5122	21.7731
BICR 31	GDSC2; CTRP2	4.5766	10.7895	2.3599	18.4181
FaDu	GDSC2; CTRP2; CCLE	4.7651	14.6993	0.6094	24.0288
Detroit 562	GDSC2; CTRP2; CCLE	4.9487	12.3252	1.9498	19.0978
SNU-46	CTRP2	5.1217	9.9492	3.2782	13.5159
PE/CA-PJ41 (clone D2)	CTRP2	5.3445	13.4313	1.7526	18.9409
BICR 16	CTRP2	5.9321	17.1039	0.4208	22.0936
BICR 18	CTRP2	6.4251	9.7183	4.5143	5.733
YD-8	CTRP2	6.5715	10.3753	4.301	6.3702
BICR 6	CTRP2	6.6599	22.2862	-1.5694	25.8429
SCC-4	GDSC2; CTRP2	7.9255	23.7217	-1.2797	22.9765

Cancer Drug Sensitivity Data Curated from 24 Cell Line(s) in Urinary Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
U-BLC1	CTRP2	-3.6585	-0.163	-3.6657	64.2955
SCaBER	CTRP2; CCLE	0.8668	6.04	0.3951	35.9045
5637	GDSC2; CTRP2; CCLE	0.9015	4.8657	0.7041	34.8876
JMSU-1	CTRP2; CCLE	2.3682	5.4825	2.1707	25.1691
253J	CTRP2	2.7315	6.9551	2.1449	24.1443
VM-CUB-1	CTRP2	3.6142	10.017	1.7923	22.9357
SW780	GDSC2; CCLE	3.688	9.3122	0.3973	11.9942
HT-1376	GDSC2; CTRP2; CCLE	3.7051	12.1096	0.8946	25.7176
CAL-29	GDSC2; CTRP2	3.7586	11.2324	1.3647	24.0459
253J-BV	CTRP2	3.9679	10.4981	1.9161	21.5722
RT-4	GDSC2; CTRP2; CCLE	5.1191	10.2809	3.1129	14.1936
UM-UC-3	GDSC2; CTRP2; CCLE	5.4005	7.9227	4.5265	7.7426
T24	GDSC2; CTRP2; CCLE	5.5674	9.98	3.6662	10.947
BC-3C	CTRP2	5.6967	11.8701	2.837	14.0672
RT-112	GDSC2; CTRP2; CCLE	5.72	10.0049	3.7877	10.1241
BFTC-905	GDSC2; CTRP2	5.9644	8.3614	4.8186	5.3089
KMBC-2	CTRP2; CCLE	6.0427	18.5418	-0.2057	23.658
SW1710	GDSC2; CTRP2	6.5295	15.097	1.9158	15.9564
TCCSUP	GDSC2; CTRP2; CCLE	7.3417	13.5065	3.3315	9.0742
HT-1197	GDSC2; CTRP2; CCLE	7.8393	12.9985	3.9255	5.9674
KU-19-19	GDSC2; CTRP2	8.5645	21.9606	0.0765	18.3923
J82	GDSC2; CTRP2; CCLE	9.21	16.8685	2.9882	7.7412
639V	GDSC2; CTRP2; CCLE	9.8294	18.7034	2.5225	8.639
647V	GDSC2; CTRP2	10.3905	24.0031	0.3779	14.8447

Cancer Drug Sensitivity Data Curated from 39 Cell Line(s) in Urogenital System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
OVCA420	GDSC2	-1.799	3.8027	-3.102	33.9582
CAL-39	GDSC2	-1.0797	3.7479	-2.3418	27.4992
OVMIU	GDSC2	0.0291	6.2866	-2.4904	23.9044
BPH-1	GDSC2	0.0509	9.559	-4.094	30.0274
DSH1	GDSC1; GDSC2	1.4525	3.2234	0.2392	3.6499
NCC-IT	GDSC1; GDSC2	1.8138	4.3613	-0.0603	4.6826
DoTc2 4510	GDSC2	2.0014	5.9208	-0.684	8.0412
PA-1	GDSC2	2.0842	7.4145	-1.3546	11.7821
C-33 A	GDSC2	2.128	7.2658	-1.2498	11.0776
TC-YIK	GDSC2	2.1469	6.052	-0.6459	7.4866
C-4-I	GDSC2	2.2294	11.5855	-3.3063	20.9167
SiHa	GDSC2	2.3983	3.4073	0.6709	0.2143
HEC-1	GDSC2	2.4012	4.065	0.4179	1.109
UWB1.289	GDSC2	2.4298	7.5768	0.4119	20.7101
NEC8	GDSC1; GDSC2	2.4522	4.0903	0.4319	0.9972
HT-3	GDSC2	2.4534	6.0865	-0.458	5.7454
PEO1	GDSC2	2.4598	6.8354	-0.8091	7.7765
LB831-BLC	GDSC1; GDSC2	2.6522	6.6027	-0.5733	6.0291
HEY	GDSC2	2.6828	9.8584	-2.1171	14.4351
PWR-1E	GDSC2	2.7425	7.3636	-0.8732	7.5669
ME-180	GDSC2	2.763	13.3498	-3.7742	21.4096
NT2-D1	GDSC1; GDSC2	2.7964	5.5302	-0.0012	2.6448
SiSo	GDSC2	2.8786	8.8374	-1.4852	10.6954
SKG-IIIa	GDSC2	2.9274	4.9342	0.3132	1.0485
SW954	GDSC1; GDSC2	3.1344	9.2306	0.2099	18.8676
OMC-1 [Human cervical carcinoma]	GDSC1; GDSC2	3.1592	5.1153	2.2863	6.8025
MS751	GDSC2	3.1809	11.8262	-2.7209	16.1613
KGN	GDSC1; GDSC2	3.582	10.4838	-1.8014	10.9094
Ca Ski	GDSC2	3.6284	12.4037	-2.6879	15.0473
SKN	GDSC2	3.8111	6.4185	0.1232	1.0651
OVCA433	GDSC2	3.9106	7.3633	1.7684	8.2325
JAR	GDSC1; GDSC2	3.9273	6.8229	2.0468	6.2476
ACC-OV7	GDSC2	3.9932	7.3037	1.859	7.4708
SW756	GDSC2	4.5945	14.1248	-2.8629	13.8995
OV17R	GDSC2	4.9912	10.0501	1.2268	8.9781
JHOS-3	GDSC2	5.0677	9.7203	1.4344	7.6419
JEG-3	GDSC2	5.3181	6.9745	2.7732	0.5175
SW962	GDSC1; GDSC2	6.1648	19.9495	-2.758	22.8736
HeLa	GDSC2; CTRP2	14.2961	38.3513	-3.8577	19.8996

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Erlotinib

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Porfimer Sodium	DM7ZWNY	Moderate	Increased risk of photosensitivity reactions by the combination of Erlotinib and Porfimer Sodium.	Lung cancer [2C25]	[13]
Ceritinib	DMB920Z	Moderate	Decreased metabolism of Erlotinib caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[14]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Erlotinib caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[14]
Capmatinib	DMYCXKL	Moderate	Decreased clearance of Erlotinib due to the transporter inhibition by Capmatinib.	Lung cancer [2C25]	[15]

Coadministration of a Drug Treating the Disease Different from Erlotinib (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Erlotinib and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[16]
Sodium bicarbonate	DMMU6BJ	Moderate	Decreased absorption of Erlotinib due to altered gastric pH caused by Sodium bicarbonate.	Acidosis [5C73]	[16]
Ivosidenib	DM8S6T7	Moderate	Increased metabolism of Erlotinib caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[14]
Midostaurin	DMI6E0R	Moderate	Decreased clearance of Erlotinib due to the transporter inhibition by Midostaurin.	Acute myeloid leukaemia [2A60]	[17]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Erlotinib caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[14]
Mitotane	DMU1GX0	Moderate	Increased metabolism of Erlotinib caused by Mitotane mediated induction of CYP450 enzyme.	Adrenal cancer [2D11]	[14]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Erlotinib and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[18]
Methylphenobarbital	DMDSWAG	Moderate	Increased metabolism of Erlotinib caused by Methylphenobarbital mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[14]
Voriconazole	DMAOL2S	Moderate	Decreased metabolism of Erlotinib caused by Voriconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[14]
Posaconazole	DMUL5EW	Moderate	Decreased metabolism of Erlotinib caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[14]
Ciprofloxacin XR	DM2NLS9	Moderate	Decreased metabolism of Erlotinib caused by Ciprofloxacin XR mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[19]
Clarithromycin	DM4M1SG	Moderate	Decreased metabolism of Erlotinib caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[14]
Rabeprazole	DMMZXIW	Major	Decreased absorption of Erlotinib due to altered gastric pH caused by Rabeprazole.	Bacterial infection [1A00-1C4Z]	[16]
Troleandomycin	DMUZNIG	Moderate	Decreased metabolism of Erlotinib caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[14]
Telithromycin	DMZ4P3A	Moderate	Decreased metabolism of Erlotinib caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[14]
Erdafitinib	DMI782S	Moderate	Decreased clearance of Erlotinib due to the transporter inhibition by Erdafitinib.	Bladder cancer [2C94]	[20]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Erlotinib and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[21]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Erlotinib caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[22]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Erlotinib caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[14]
PF-04449913	DMSB068	Moderate	Decreased clearance of Erlotinib due to the transporter inhibition by PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[17]
Phenylbutazone	DMAYL0T	Moderate	Increased metabolism of Erlotinib caused by Phenylbutazone mediated induction of CYP450 enzyme.	Chronic pain [MG30]	[14]
Anisindione	DM2C48U	Moderate	Increased plasma concentration of Erlotinib and Anisindione due to competitive binding of plasma proteins.	Coagulation defect [3B10]	[19]
Lumacaftor	DMCLWDJ	Moderate	Increased metabolism of Erlotinib caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[14]
Ivacaftor	DMZC1HS	Moderate	Decreased clearance of Erlotinib due to the transporter inhibition by Ivacaftor.	Cystic fibrosis [CA25]	[23]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Erlotinib caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[24]
Nefazodone	DM4ZS8M	Moderate	Decreased metabolism of Erlotinib caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[14]
SODIUM CITRATE	DMHPD2Y	Moderate	Decreased absorption of Erlotinib due to altered gastric pH caused by SODIUM CITRATE.	Discovery agent [N.A.]	[16]
Primidone	DM0WX6I	Moderate	Increased metabolism of Erlotinib caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[14]
Felbamate	DM1V5ZS	Moderate	Increased metabolism of Erlotinib caused by Felbamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[14]
Oxcarbazepine	DM5PU6O	Moderate	Increased metabolism of Erlotinib caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[14]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Erlotinib caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[14]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Erlotinib caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[14]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Erlotinib caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[14]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Erlotinib caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[14]
Carbamazepine	DMZOLBI	Moderate	Increased metabolism of Erlotinib caused by Carbamazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[14]
Eslicarbazepine	DMZREFQ	Moderate	Increased metabolism of Erlotinib caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[14]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Erlotinib and Cannabidiol.	Epileptic encephalopathy [8A62]	[17]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Erlotinib caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[14]
Itraconazole	DMCR1MV	Moderate	Decreased metabolism of Erlotinib caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[14]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Erlotinib caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[14]
Ketoconazole	DMPZI3Q	Moderate	Decreased metabolism of Erlotinib caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[14]
Dexlansoprazole	DM1DBV5	Major	Decreased absorption of Erlotinib due to altered gastric pH caused by Dexlansoprazole.	Gastro-oesophageal reflux disease [DA22]	[16]
Nizatidine	DMGFV3Z	Moderate	Decreased absorption of Erlotinib due to altered gastric pH caused by Nizatidine.	Gastro-oesophageal reflux disease [DA22]	[16]
Sulfinpyrazone	DMEV954	Moderate	Increased metabolism of Erlotinib caused by Sulfinpyrazone mediated induction of CYP450 enzyme.	Gout [FA25]	[14]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Erlotinib caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[14]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Erlotinib caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[14]
GS-5885	DMSL3DX	Moderate	Decreased clearance of Erlotinib due to the transporter inhibition by GS-5885.	Hepatitis virus infection [1E50-1E51]	[25]
Isoniazid	DM5JVS3	Moderate	Decreased metabolism of Erlotinib caused by Isoniazid mediated inhibition of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[19]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Erlotinib caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[14]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Erlotinib caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[14]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Erlotinib and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[26]
Delavirdine	DM3NF5G	Moderate	Decreased metabolism of Erlotinib caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[14]
Fosamprenavir	DM4W9B3	Moderate	Decreased metabolism of Erlotinib caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[14]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Erlotinib caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[14]
Efavirenz	DMC0GSJ	Moderate	Increased metabolism of Erlotinib caused by Efavirenz mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[14]
Saquinavir	DMG814N	Moderate	Decreased metabolism of Erlotinib caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[14]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Erlotinib caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[14]
Amprenavir	DMLMXE0	Moderate	Decreased metabolism of Erlotinib caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[14]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Erlotinib caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[27]
Atazanavir	DMSYRBX	Moderate	Decreased metabolism of Erlotinib caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[14]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Erlotinib and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[28]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Erlotinib and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[29]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Erlotinib and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[30]
Sodium zirconium cyclosilicate	DMCSLZ4	Moderate	Decreased absorption of Erlotinib due to altered gastric pH caused by Sodium zirconium cyclosilicate.	Hyperkalaemia [5C76]	[17]
Verapamil	DMA7PEW	Moderate	Decreased metabolism of Erlotinib caused by Verapamil mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[19]
Conivaptan	DM1V329	Moderate	Decreased metabolism of Erlotinib caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[14]
Tolvaptan	DMIWFRL	Moderate	Decreased clearance of Erlotinib due to the transporter inhibition by Tolvaptan.	Hypo-osmolality/hyponatraemia [5C72]	[16]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Erlotinib caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[14]
Methotrexate	DM2TEOL	Moderate	Increased risk of hepatotoxicity by the combination of Erlotinib and Methotrexate.	Leukaemia [2A60-2B33]	[17]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Erlotinib and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[31]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Erlotinib and Idelalisib.	Mature B-cell leukaemia [2A82]	[32]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Erlotinib caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[33]
Clofarabine	DMCVJ86	Moderate	Increased risk of hepatotoxicity by the combination of Erlotinib and Clofarabine.	Mature B-cell lymphoma [2A85]	[34]
Ibrutinib	DMHZCPO	Moderate	Decreased clearance of Erlotinib due to the transporter inhibition by Ibrutinib.	Mature B-cell lymphoma [2A85]	[17]
Vemurafenib	DM62UG5	Moderate	Increased metabolism of Erlotinib caused by Vemurafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[14]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Erlotinib caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[14]
Lasmiditan	DMXLVDT	Moderate	Decreased clearance of Erlotinib due to the transporter inhibition by Lasmiditan.	Migraine [8A80]	[35]
Exjade	DMHPRWG	Moderate	Increased metabolism of Erlotinib caused by Exjade mediated induction of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[14]
Rifabutin	DM1YBHK	Moderate	Increased metabolism of Erlotinib caused by Rifabutin mediated induction of CYP450 enzyme.	Mycobacterium infection [1B10-1B21]	[14]
Methoxsalen	DME8FZ9	Moderate	Increased risk of photosensitivity reactions by the combination of Erlotinib and Methoxsalen.	Mycosis fungoides [2B01]	[16]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Erlotinib caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[36]
Dasatinib	DMJV2EK	Moderate	Decreased metabolism of Erlotinib caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[37]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive immunosuppressive effects by the combination of Erlotinib and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[38]
Modafinil	DMYILBE	Minor	Increased metabolism of Erlotinib caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[39]
Rolapitant	DM8XP26	Moderate	Decreased clearance of Erlotinib due to the transporter inhibition by Rolapitant.	Nausea/vomiting [MD90]	[40]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Erlotinib caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[41]
Ranitidine	DM0GUSX	Moderate	Decreased absorption of Erlotinib due to altered gastric pH caused by Ranitidine.	Peptic ulcer [DA61]	[16]
Esomeprazole	DM7BN0X	Major	Decreased absorption of Erlotinib due to altered gastric pH caused by Esomeprazole.	Peptic ulcer [DA61]	[16]
Famotidine	DMRL3AB	Moderate	Decreased absorption of Erlotinib due to altered gastric pH caused by Famotidine.	Peptic ulcer [DA61]	[16]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Erlotinib caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[42]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Erlotinib caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[14]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Erlotinib caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[14]
Bosentan	DMIOGBU	Moderate	Increased metabolism of Erlotinib caused by Bosentan mediated induction of CYP450 enzyme.	Pulmonary hypertension [BB01]	[14]
Riociguat	DMXBLMP	Moderate	Decreased metabolism of Erlotinib caused by Riociguat mediated inhibition of CYP450 enzyme.	Pulmonary hypertension [BB01]	[29]
Dexamethasone	DMMWZET	Moderate	Increased metabolism of Erlotinib caused by Dexamethasone mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[14]
Nafcillin	DMN9RPO	Moderate	Increased metabolism of Erlotinib caused by Nafcillin mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[14]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Erlotinib and Leflunomide.	Rheumatoid arthritis [FA20]	[29]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Erlotinib caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[17]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Erlotinib caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[16]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Erlotinib and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[17]
Armodafinil	DMGB035	Minor	Increased metabolism of Erlotinib caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[39]
Naltrexone	DMUL45H	Moderate	Increased risk of hepatotoxicity by the combination of Erlotinib and Naltrexone.	Substance abuse [6C40]	[43]
Warfarin	DMJYCVW	Moderate	Increased plasma concentrations of Erlotinib and Warfarin due to competitive inhibition of the same metabolic pathway.	Supraventricular tachyarrhythmia [BC81]	[19]
Fostamatinib	DM6AUHV	Moderate	Decreased clearance of Erlotinib due to the transporter inhibition by Fostamatinib.	Thrombocytopenia [3B64]	[44]
Elagolix	DMB2C0E	Moderate	Increased metabolism of Erlotinib caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[14]
Amiodarone	DMUTEX3	Moderate	Decreased metabolism of Erlotinib caused by Amiodarone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[19]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Erlotinib 25 mg tablet	25 mg	Oral Tablet	Oral
Erlotinib 100 mg tablet	100 mg	Oral Tablet	Oral
Erlotinib 150 mg tablet	150 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Erlotinib FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4920).
• [3] BDDCS applied to over 900 drugs
• [4] Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
• [5] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [6] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [7] Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.
• [8] Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. Adv Drug Deliv Rev. 2009 Jan 31;61(1):26-33.
• [9] Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Mol Cancer Ther. 2008 Aug;7(8):2280-7.
• [10] In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors. Drug Metab Dispos. 2014 Jul;42(7):1202-9.
• [11] Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.
• [12] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004 May 20;350(21):2129-39. doi: 10.1056/NEJMoa040938. Epub 2004 Apr 29.
• [13] Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
• [14] Li J, Zhao M, He P, Hidalgo M, Baker SD "Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes." Clin Cancer Res 13 (2007): 3731-7. [PMID: 17575239]
• [15] Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [16] Cerner Multum, Inc. "Australian Product Information.".
• [17] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [18] Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
• [19] Product Information. Tarceva (erlotinib). Genentech, South San Francisco, CA.
• [20] Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
• [21] Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
• [22] Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [23] Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
• [24] Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
• [25] Product Information. Harvoni (ledipasvir-sofosbuvir). Gilead Sciences, Foster City, CA.
• [26] Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
• [27] Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
• [28] Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
• [29] Canadian Pharmacists Association.
• [30] Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
• [31] Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
• [32] Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
• [33] Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
• [34] Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
• [35] Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
• [36] Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [37] Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
• [38] Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
• [39] Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
• [40] Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
• [41] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [42] Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
• [43] Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
• [44] Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.